



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/18, 15/56, 15/86, 5/10, 9/24, C07K 14/505, A61K 31/70, 48/00	A1	(11) International Publication Number: WO 97/26337 (43) International Publication Date: 24 July 1997 (24.07.97)
(21) International Application Number: PCT/US97/00895 (22) International Filing Date: 17 January 1997 (17.01.97) (30) Priority Data: 08/588,355 18 January 1996 (18.01.96) US 08/784,757 16 January 1997 (16.01.97) US (71) Applicants: AVIGEN, INC. [US/US]; Suite 1000, 1201 Harbor Bay Parkway, Alameda, CA 94501 (US). JOHNS HOPKINS UNIVERSITY [US/US]; 720 Rutland Avenue, Baltimore, MD 21205 (US). (72) Inventors: PODSAKOFF, Gregory, M.; 2832 Teal Drive, Fullerton, CA 92635 (US). KESSLER, Paul, D.; 7907 Ellenham Avenue, Baltimore, MD 21204 (US). BYRNE, Barry, J.; 814 Chumleigh Road, Baltimore, MD 21212 (US). KURTZMAN, Gary, J.; 24 Campbell Lane, Menlo Park, CA 94025 (US). (74) Agents: McCracken, Thomas, P. et al.; Robins & Associates, Suite 200, 90 Middlefield Road, Menlo Park, CA 94025 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHODS FOR DELIVERING DNA TO MUSCLE CELLS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VIRIONS		
(57) Abstract The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, <i>in vivo</i> injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the <i>in vitro</i> transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for <i>in vivo</i> secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5 METHODS FOR DELIVERING DNA TO MUSCLE CELLS
 USING RECOMBINANT ADENO-ASSOCIATED VIRUS VIRIONS

Description

10 Technical Field

 The present invention relates generally to DNA delivery methods. More particularly, the invention relates to the use of recombinant adeno-associated virus (AAV) virions for delivery of a
15 selected gene to muscle cells and tissue. The method provides for sustained, high-level expression of the delivered gene.

Background of the Invention

20 Gene delivery is a promising method for the treatment of acquired and inherited diseases. Muscle tissue is an appealing gene delivery target because it is readily accessible, well-differentiated and nondividing. Barr and Leiden (1991) *Science*
25 254:1507-1509. These properties are important in the selection of appropriate delivery strategies to achieve maximal gene transfer.

 Several experimenters have demonstrated the ability to deliver genes to muscle cells with the
30 subsequent systemic circulation of proteins encoded by the delivered genes. See, e.g., Wolff et al. (1990) *Science* 247:1465-1468; Acsadi et al. (1991) *Nature* 352:815-818; Barr and Leiden (1991) *Science* 254:1507-1509; Dhawan et al. (1991) *Science* 254:1509-1512;
35 Wolff et al. (1992) *Human Mol. Genet.* 1:363-369; Eyal et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:4523-4527; Davis et al. (1993) *Hum. Gene Therapy* 4:151-159.

Genes have been delivered to muscle by direct injection of plasmid DNA, such as described by Wolff et al. (1990) *Science* 247:1465-1468; Acsadi et al. (1991) *Nature* 352:815-818; Barr and Leiden (1991) *Science* 254:1507-1509. However, this mode of administration generally results in sustained but low levels of expression. Low but sustained expression levels may be effective in certain situations, such as for providing immunity.

Viral based systems have also been used for gene delivery to muscle. For example, human adenoviruses are double-stranded DNA viruses which enter cells by receptor-mediated endocytosis. These viruses have been considered well suited for gene transfer because they are easy to grow and manipulate and they exhibit a broad host range *in vivo* and *in vitro*. Adenoviruses are able to infect quiescent as well as replicating target cells and persist extrachromosomally, rather than integrating into the host genome.

Despite these advantages, adenovirus vectors suffer from several drawbacks which make them ineffective for long term gene therapy. In particular, adenovirus vectors express viral proteins that may elicit an immune response which may decrease the life of the transduced cell. This immune reaction may preclude subsequent treatments because of humoral and/or T cell responses. Furthermore, the adult muscle cell may lack the receptor which recognizes adenovirus vectors, precluding efficient transduction of this cell type using such vectors.

Thus, attempts to use adenoviral vectors for the delivery of genes to muscle cells has resulted in poor and/or transitory expression. See, e.g., Quantin et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:2581-2584; Acsadi et al. (1994) *Hum. Mol. Genetics* 3:579-584; Acsadi et al. (1994) *Gene Therapy* 1:338-340; Dai et

al. (1995) *Proc. Natl. Acad. Sci. USA* 92:1401-1405;
Descamps et al. (1995) *Gene Therapy* 2:411-417;
Gilgenkrantz et al. (1995) *Hum. Gene Therapy* 6:1265-
1274.

5 Gene therapy methods based upon surgical
transplantation of myoblasts has also been attempted.
See, e.g., International Publication no. WO 95/13376;
Dhawan et al. (1991) *Science* 254:1509-1512; Wolff et
al. (1992) *Human Mol. Genet.* 1:363-369; Dai et al.
10 (1992) *Proc. Natl. Acad. Sci. USA* 89:10892-10895;
Hamamori et al. (1994) *Hum. Gene Therapy* 5:1349-1356;
Hamamori et al. (1995) *J. Clin. Invest.* 95:1808-1813;
Blau and Springer (1995) *New Eng. J. Med.* 333:1204-
1207; Leiden, J.M. (1995) *New Eng. J. Med.* 333:871-
15 872; Mendell et al. (1995) *New Eng. J. Med.* 333:832-
838; and Blau and Springer (1995) *New Eng. J. Med.*
333:1554-1556. However, such methods require
substantial tissue culture manipulation and surgical
expertise, and, at best, show inconclusive efficacy in
20 clinical trials. Thus, a simple and effective method
of gene delivery to muscle, resulting in long-term
expression of the delivered gene, would be desirable.

Recombinant vectors derived from an adeno-
associated virus (AAV) have been used for gene
25 delivery. AAV is a helper-dependent DNA parvovirus
which belongs to the genus *Dependovirus*. AAV requires
infection with an unrelated helper virus, such as
adenovirus, a herpesvirus or vaccinia, in order for a
productive infection to occur. The helper virus
30 supplies accessory functions that are necessary for
most steps in AAV replication. In the absence of such
infection, AAV establishes a latent state by insertion
of its genome into a host cell chromosome. Subsequent
infection by a helper virus rescues the integrated
35 copy which can then replicate to produce infectious
viral progeny. AAV has a wide host range and is able
to replicate in cells from any species so long as

there is also a successful infection of such cells with a suitable helper virus. Thus, for example, human AAV will replicate in canine cells coinfecting with a canine adenovirus. AAV has not been associated with any human or animal disease and does not appear to alter the biological properties of the host cell upon integration. For a review of AAV, see, e.g., Berns and Bohenzky (1987) *Advances in Virus Research* (Academic Press, Inc.) 32:243-307.

10 The AAV genome is composed of a linear, single-stranded DNA molecule which contains approximately 4681 bases (Berns and Bohenzky, *supra*). The genome includes inverted terminal repeats (ITRs) at each end which function in *cis* as origins of DNA replication and as packaging signals for the virus. 15 The internal nonrepeated portion of the genome includes two large open reading frames, known as the AAV *rep* and *cap* regions, respectively. These regions code for the viral proteins involved in replication and packaging of the virion. For a detailed 20 description of the AAV genome, see, e.g., Muzyczka, N. (1992) *Current Topics in Microbiol. and Immunol.* 158:97-129.

 The construction of recombinant AAV (rAAV) virions has been described. See, e.g., U.S. Patent 25 Nos. 5,173,414 and 5,139,941; International Publication Numbers WO 92/01070 (published 23 January 1992) and WO 93/03769 (published 4 March 1993); Lebkowski et al. (1988) *Molec. Cell. Biol.* 8:3988-30 3996; Vincent et al. (1990) *Vaccines 90* (Cold Spring Harbor Laboratory Press); Carter, B.J. (1992) *Current Opinion in Biotechnology* 3:533-539; Muzyczka, N. (1992) *Current Topics in Microbiol. and Immunol.* 158:97-129; and Kotin, R.M. (1994) *Human Gene Therapy* 35 5:793-801.

 Recombinant AAV virion production generally involves cotransfection of a producer cell with an AAV

vector plasmid and a helper construct which provides AAV helper functions to complement functions missing from the AAV vector plasmid. In this manner, the producer cell is capable of expressing the AAV proteins necessary for AAV replication and packaging. The AAV vector plasmid will include the DNA of interest flanked by AAV ITRs which provide for AAV replication and packaging functions. AAV helper functions can be provided via an AAV helper plasmid that includes the AAV *rep* and/or *cap* coding regions but which lacks the AAV ITRs. Accordingly, the helper plasmid can neither replicate nor package itself. The producer cell is then infected with a helper virus to provide accessory functions, or with a vector which includes the necessary accessory functions. The helper virus transactivates the AAV promoters present on the helper plasmid that direct the transcription and translation of AAV *rep* and *cap* regions. Upon subsequent culture of the producer cells, recombinant AAV virions harboring the DNA of interest, are produced.

Recombinant AAV virions have been shown to exhibit tropism for respiratory epithelial cells (Flotte et al. (1992) *Am. J. Respir. Cell Mol. Biol.* 7:349-356; Flotte et al. (1993) *J. Biol. Chem.* 268:3781-3790; Flotte et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:10613-10617) and neurons of the central nervous system (Kaplitt et al. (1994) *Nature Genetics* 8:148-154). These cell types are well-differentiated, slowly-dividing or postmitotic. Flotte et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:10613-10617; Kaplitt et al. (1994) *Nature Genetics* 8:148-154. The ability of AAV vectors to transduce nonproliferating cells (Podsakoff et al. (1994) *J. Virol.* 68:5656-5666; Russell et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:8915-8919; Flotte et al. (1994) *Am. J. Respir. Cell Mol. Biol.* 11:517-521) along with the attributes of

being inherently defective and nonpathogenic, place AAV in a unique position among gene therapy viral vectors.

Despite these advantages, the use of recombinant AAV virions to deliver genes to muscle cells *in vivo* has not heretofore been disclosed.

Summary of the Invention

Accordingly, the present invention is based on the surprising and unexpected discovery that recombinant AAV (rAAV) virions provide for efficient delivery of genes and sustained production of therapeutic proteins in various muscle cell types. The invention allows for *in vivo* secretion of the therapeutic protein from transduced muscle cells such that systemic delivery of therapeutic levels of the protein is achieved. These results are seen with both *in vivo* and *in vitro* modes of DNA delivery. Hence, rAAV virions allow delivery of DNA directly to muscle tissue. The ability to deliver and express genes in muscle cells, as well as to provide for secretion of the produced protein from transduced cells, allows the use of gene therapy approaches to treat and/or prevent a wide variety of disorders.

Furthermore, the ability to deliver DNA to muscle cells by intramuscular administration *in vivo* provides a more efficient and convenient method of gene transfer.

Thus, in one embodiment, the invention relates to a method of delivering a selected gene to a muscle cell or tissue. The method comprises:

(a) providing a recombinant AAV virion which comprises an AAV vector, the AAV vector comprising the selected gene operably linked to control elements capable of directing the *in vivo* transcription and translation of the selected gene; and

(b) introducing the recombinant AAV virion into the muscle cell or tissue.

In particularly preferred embodiments, the selected gene encodes a therapeutic protein, such as erythropoietin (EPO), or the lysosomal enzyme, acid α -glucosidase (GAA).

In another embodiment, the invention is directed to a muscle cell or tissue transduced with a recombinant AAV virion which comprises an AAV vector, the AAV vector comprising a selected gene operably linked to control elements capable of directing the *in vivo* transcription and translation of the selected gene.

In still further embodiments, the invention is directed to a method of treating an acquired or inherited disease in a mammalian subject comprising introducing into a muscle cell or tissue of the subject, *in vivo*, a therapeutically effective amount of a pharmaceutical composition which comprises (a) a pharmaceutically acceptable excipient; and (b) recombinant AAV virions. The recombinant AAV virions comprise an AAV vector, the AAV vector comprising a selected gene operably linked to control elements capable of directing the transcription and translation of the selected gene when present in the subject.

In yet another embodiment, the invention is directed to a method of treating an acquired or inherited disease in a mammalian subject comprising:

(a) introducing a recombinant AAV virion into a muscle cell or tissue *in vitro* to produce a transduced muscle cell. The recombinant AAV virion comprises an AAV vector, the AAV vector comprising a selected gene operably linked to control elements capable of directing the transcription and translation of the selected gene when present in the subject; and

(b) administering to the subject a therapeutically effective amount of a composition

comprising a pharmaceutically acceptable excipient and the transduced muscle cells from step (a).

In a further embodiment, the invention relates to a method for delivering a therapeutically effective amount of a protein systemically to a mammalian subject comprising introducing into a muscle cell or tissue of the subject a pharmaceutical composition which comprises (a) a pharmaceutically acceptable excipient; and (b) recombinant AAV virions, wherein the recombinant AAV virions comprise an AAV vector, the AAV vector comprising a selected gene operably linked to control elements capable of directing the transcription and translation of the selected gene when present in the subject, wherein the introducing is done *in vivo*.

In another embodiment, the invention is directed to a method for delivering a therapeutically effective amount of a protein systemically to a mammalian subject comprising:

(a) introducing a recombinant AAV virion into a muscle cell or tissue *in vitro* to produce a transduced muscle cell, wherein the recombinant AAV virion comprises an AAV vector, the AAV vector comprising a selected gene operably linked to control elements capable of directing the transcription and translation of the selected gene when present in the subject; and

(b) administering to the subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable excipient and the transduced muscle cells from step (a).

In other embodiments, the invention is directed to an AAV vector comprising a gene encoding either erythropoietin (EPO), or acid α -glucosidase (GAA), operably linked to control elements capable of directing the *in vivo* transcription and translation of

the gene, as well as a recombinant AAV (rAAV) virion comprising the vector.

These and other embodiments of the subject invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.

Brief Description of the Figures

Figure 1 shows *in situ* histochemical detection of β -galactosidase expression in murine muscle cells following transduction with rAAV-LacZ as described in Example 3, Part A. In the study, the tibialis anterior muscle of adult Balb/c mice was injected with 8×10^9 rAAV-LacZ. Animals were sacrificed (a) 2, (b) 4, (c) 8, (d) 12, (e) 24, of (f) 32 weeks after injection. The tibialis anterior was excised, and 10 mm sections were stained by X-gal for β -galactosidase histochemistry. The stained tissue samples were photographed at 25X.

Figure 2 shows a section of skeletal muscle two months after injection with rAAV-LacZ as described in Example 3, Part A. The tibialis anterior muscle was processed for *in situ* detection of β -galactosidase expression, and photographed with diffraction-interference contrast optics at 400X.

Figure 3 depicts β -galactosidase expression in Balb/c mice tibialis anterior muscle transduced *in vivo* with rAAV-LacZ as described in Example 3, Part B. Adult Balb/c mice were injected intramuscularly (IM) with various doses of rAAV-LacZ. At 2 and 8 weeks post injection, tissue was harvested for analysis of beta-galactosidase (β -gal). β -gal expression was analyzed by measurement of relative light units (RLU) emitted from muscle homogenates, as detected by luminometer.

Figure 4 shows the secretion of human erythropoietin (hEPO) from transduced myotubes and myoblasts, as described in Example 4. Myotubes

(differentiated cells) or myoblasts (actively dividing cells) were transduced with rAAV-hEPO at a ratio of approximately 10^5 per target cell. Levels of secreted hEPO were analyzed in supernatants at various time points. Baseline levels of hEPO prior to transduction were below the level of detection in both cell populations; the values at each time point represent replicate values \pm standard deviation.

Figure 5 shows the secretion of human erythropoietin (hEPO) by C2C12 myotubes transduced with rAAV-hEPO as described in Example 4. Confluent C2C12 myoblasts were differentiated into myotubes and transduced with 3×10^8 (open bar), 3×10^9 (cross-hatched bar), or 3×10^{10} (solid bar) rAAV-hEPO. Secretion of EPO was measured 3, 8, and 14 days after transduction. Control rAAV-LacZ myotubes secreted <2.5 mU/mL EPO. The bar graph depicts mean production of EPO/well/24 hour as determined in triplicate cultures \pm the standard error of mean (SEM).

Figure 6 shows the secretion of human erythropoietin (hEPO) by primary human myotubes transduced with rAAV-hEPO as described in Example 5. Confluent human myoblasts were differentiated into myotubes by culture for 14 days in reduced-serum media, then transduced with 3×10^8 (open bar), 3×10^9 (cross-hatched bar), or 3×10^{10} (solid bar) rAAV-hEPO. Secretion of EPO was measured 3, 8 and 14 days after transduction. Control myotubes transduced with rAAV-LacZ secreted <2.5 mU/mL EPO. The bar graph depicts mean production of EPO/well/24 hour as determined in triplicate cultures \pm SEM.

Figure 7 depicts the time course of EPO secretion in Balb/c mice after IM injection with rAAV-hEPO. Adult Balb/c mice were injected IM with 1×10^{10} (∇), 3×10^{10} (\blacktriangle), 1×10^{11} (\blacksquare), or 3×10^{11} (\bullet) purified rAAV-LacZ at day = 0, and serum EPO levels

measured at various time points after injection.
Reported values represent means (n=4) \pm SEM.

Figure 8 shows high level expression of acid α -glucosidase (GAA) in human skeletal muscle transduced *in vitro* with rAAV-hGAA as described in Example 8, Part A. In the study, differentiated human myoblasts were exposed to rAAV-hGAA virions at a MOI of 2×10^5 . Cells were collected at the time points indicated, and GAA activity measured by enzymatic assay. Non-transduced control cells (open bar) and cells transduced with rAAV-LacZ (cross-hatched bar) showed no significant expression of GAA, while cells transduced with rAAV-hGAA (solid bar) showed high levels of GAA activity. The bar graph represents mean GAA activity determined in triplicate cultures \pm SEM.

Figure 9 shows expression of acid α -glucosidase in Balb/c mice tibialis anterior muscle cells that were transduced *in vivo* with rAAV-hGAA, as described in Example 8, Part B. Adult Balb/c mice were injected intramuscularly (IM) with 4×10^{10} rAAV-hGAA (solid bar) or the same dose of rAAV-LacZ (open bar). At various time points after injection, muscle tissue was harvested for analysis of GAA activity by enzymatic assay. The bar graph shows mean GAA activity determined in five animals (weeks 1 and 4), or in four animals (week 10) \pm SEM.

Detailed Description of the Invention

The practice of the present invention will employ, unless otherwise indicated, conventional methods of virology, microbiology, molecular biology and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, et al. *Molecular Cloning: A Laboratory Manual* (Current Edition); *DNA Cloning: A Practical Approach*, vol. I & II (D. Glover, ed.); *Oligonucleotide Synthesis* (N. Gait, ed.,

Current Edition); *Nucleic Acid Hybridization* (B. Hames & S. Higgins, eds., Current Edition); *Transcription and Translation* (B. Hames & S. Higgins, eds., Current Edition); *CRC Handbook of Parvoviruses*, vol. I & II (P. Tijssen, ed.); *Fundamental Virology*, 2nd Edition, vol. I & II (B.N. Fields and D.M. Knipe, eds.)

As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise.

A. Definitions

In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

The phrase "gene delivery" or "gene transfer" refers to methods or systems for reliably inserting foreign DNA into target cells, such as into muscle cells. Such methods can result in transient or long term expression of genes. Gene transfer provides a unique approach for the treatment of acquired and inherited diseases. A number of systems have been developed for gene transfer into mammalian cells. See, e.g., U.S. Patent No. 5,399,346.

The term "therapeutic protein" refers to a protein which is defective or missing from the subject in question, thus resulting in a disease state or disorder in the subject, or to a protein which confers a benefit to the subject in question, such as an antiviral, antibacterial or antitumor function. A therapeutic protein can also be one which modifies any one of a wide variety of biological functions, such as endocrine, immunological and metabolic functions. Representative therapeutic proteins are discussed more fully below.

By "vector" is meant any genetic element, such as a plasmid, phage, transposon, cosmid,

chromosome, virus, virion, etc., which is capable of replication when associated with the proper control elements and which can transfer gene sequences between cells. Thus, the term includes cloning and expression vehicles, as well as viral vectors.

By "AAV vector" is meant a vector derived from an adeno-associated virus serotype, including without limitation, AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAVX7, etc. AAV vectors can have one or more of the AAV wild-type genes deleted in whole or part, preferably the rep and/or cap genes (described below), but retain functional flanking ITR sequences (also described below). Functional ITR sequences are necessary for the rescue, replication and packaging of the AAV virion. Thus, an AAV vector is defined herein to include at least those sequences required in cis for replication and packaging (e.g., functional ITRs) of the virus. The ITRs need not be the wild-type nucleotide sequences, and may be altered, e.g., by the insertion, deletion or substitution of nucleotides, so long as the sequences provide for functional rescue, replication and packaging.

By "recombinant virus" is meant a virus that has been genetically altered, e.g., by the addition or insertion of a heterologous nucleic acid construct into the particle.

By "AAV virion" is meant a wild-type (wt) AAV virus particle (comprising a linear, single-stranded AAV nucleic acid genome associated with an AAV capsid protein coat). In this regard, single-stranded AAV nucleic acid molecules of either complementary sense, e.g., "sense" or "antisense" strands, can be packaged into any one AAV virion and both strands are equally infectious.

A "recombinant AAV virion," or "rAAV virion" is defined herein as an infectious, replication-defective virus composed of an AAV protein shell,

encapsidating a DNA molecule of interest which is flanked on both sides by AAV ITRs. An rAAV virion is produced in a suitable producer cell which has had an AAV vector, AAV helper functions and accessory functions introduced therein. In this manner, the producer cell is rendered capable of encoding AAV polypeptides that are required for packaging the AAV vector (containing a recombinant nucleotide sequence of interest) into recombinant virion particles for subsequent gene delivery.

The term "transfection" is used to refer to the uptake of foreign DNA by a mammalian cell. A cell has been "transfected" when exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are known in the art. See, e.g., Graham et al. (1973) *Virology*, 52:456, Sambrook et al. (1989) *Molecular Cloning, a laboratory manual*, Cold Spring Harbor Laboratories, New York, Davis et al. (1986) *Basic Methods in Molecular Biology*, Elsevier, and Chu et al. (1981) *Gene* 13:197. Such techniques can be used to introduce one or more exogenous DNA moieties, such as a plasmid vector and other nucleic acid molecules, into suitable cells. The term refers to both stable and transient uptake of the genetic material.

The term "transduction" denotes the delivery of a DNA molecule to a recipient cell either *in vivo* or *in vitro*, via a replication-defective viral vector, such as via a recombinant AAV virion.

By "muscle cell" or "tissue" is meant a cell or group of cells derived from muscle, including but not limited to cells and tissue derived from skeletal muscle; smooth muscle, e.g., from the digestive tract, urinary bladder and blood vessels; and cardiac muscle. The term captures muscle cells both *in vitro* and *in vivo*. Thus, for example, an isolated cardiomyocyte would constitute a "muscle cell" for purposes of the

present invention, as would a muscle cell as it exists in muscle tissue present in a subject *in vivo*. The term also encompasses both differentiated and nondifferentiated muscle cells, such as myocytes, myotubes, myoblasts, cardiomyocytes and cardiomyoblasts.

The term "heterologous" as it relates to nucleic acid sequences such as gene sequences and control sequences, denotes sequences that are not normally joined together, and/or are not normally associated with a particular cell. Thus, a "heterologous" region of a nucleic acid construct or a vector is a segment of nucleic acid within or attached to another nucleic acid molecule that is not found in association with the other molecule in nature. For example, a heterologous region of a nucleic acid construct could include a coding sequence flanked by sequences not found in association with the coding sequence in nature. Another example of a heterologous coding sequence is a construct in which the coding sequence itself is not found in nature (e.g., synthetic sequences having codons different from the native gene). Similarly, a cell transformed with a construct which is not normally present in the cell would be considered heterologous for purposes of this invention. Allelic variation or naturally occurring mutational events do not give rise to heterologous DNA, as used herein.

By "DNA" is meant a polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in double-stranded or single-stranded form, either relaxed and supercoiled. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes single- and double-stranded DNA found, *inter alia*, in linear DNA molecules (e.g., restriction fragments), viruses,

plasmids, and chromosomes. In discussing the structure of particular DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having the sequence homologous to the mRNA). The term captures molecules that include the four bases adenine, guanine, thymine, or cytosine, as well as molecules that include base analogues which are known in the art.

A "gene" or "coding sequence" or a sequence which "encodes" a particular protein, is a nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide *in vitro* or *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the gene are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A gene can include, but is not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence will usually be located 3' to the gene sequence.

The term "control elements" refers collectively to promoter regions, polyadenylation signals, transcription termination sequences, upstream regulatory domains, origins of replication, internal ribosome entry sites ("IRES"), enhancers, and the like, which collectively provide for the replication, transcription and translation of a coding sequence in a recipient cell. Not all of these control elements need always be present so long as the selected coding sequence is capable of being replicated, transcribed and translated in an appropriate host cell.

The term "promoter region" is used herein in its ordinary sense to refer to a nucleotide region

comprising a DNA regulatory sequence, wherein the regulatory sequence is derived from a gene which is capable of binding RNA polymerase and initiating transcription of a downstream (3'-direction) coding sequence.

"Operably linked" refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, control elements operably linked to a coding sequence are capable of effecting the expression of the coding sequence. The control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.

For the purpose of describing the relative position of nucleotide sequences in a particular nucleic acid molecule throughout the instant application, such as when a particular nucleotide sequence is described as being situated "upstream," "downstream," "3'," or "5'" relative to another sequence, it is to be understood that it is the position of the sequences in the "sense" or "coding" strand of a DNA molecule that is being referred to as is conventional in the art.

"Homology" refers to the percent of identity between two polynucleotide or two polypeptide moieties. The correspondence between the sequence from one moiety to another can be determined by techniques known in the art. For example, homology can be determined by a direct comparison of the sequence information between two polypeptide molecules by aligning the sequence information and using readily available computer programs. Alternatively, homology

can be determined by hybridization of polynucleotides under conditions which form stable duplexes between homologous regions, followed by digestion with single-stranded-specific nuclease(s), and size determination of the digested fragments. Two DNA, or two polypeptide sequences are "substantially homologous" to each other when at least about 80%, preferably at least about 90%, and most preferably at least about 95% of the nucleotides or amino acids match over a defined length of the molecules, as determined using the methods above.

By "mammalian subject" is meant any member of the class *Mammalia* including, without limitation, humans and nonhuman primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.

B. General Methods

The present invention provides for the successful transfer of a selected gene to a muscle cell using recombinant AAV virions. The method allows for the direct, *in vivo* injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the *in vitro* transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention also provides for secretion of the produced protein *in vivo*, from transduced muscle cells, such that systemic delivery can be achieved.

Muscle provides a desirable target for gene therapy since muscle cells are readily accessible and

nondividing. However, the present invention also finds use with nondifferentiated muscle cells, such as myoblasts, which can be transduced *in vitro*, and subsequently introduced into a subject.

5 Since muscle has ready access to the circulatory system, a protein produced and secreted by muscle cells and tissue *in vivo* will enter the bloodstream for systemic delivery. Furthermore, since sustained, therapeutic levels of protein secretion
10 from muscle is achieved *in vivo* using the present invention, repeated parenteral delivery is avoided or reduced in frequency such that therapy can be accomplished using only one or few injections. Thus, the present invention provides significant advantages
15 over prior gene delivery methods.

 The recombinant AAV virions of the present invention, including the DNA of interest, can be produced using standard methodology, known to those of skill in the art. The methods generally involve the
20 steps of (1) introducing an AAV expression vector into a producer cell; (2) introducing an AAV helper construct into the producer cell, where the helper construct includes AAV coding regions capable of being expressed in the producer cell to complement AAV
25 helper functions missing from the AAV vector; (3) introducing one or more helper viruses and/or accessory function vectors into the producer cell, wherein the helper virus and/or accessory function vectors provide accessory functions capable of
30 supporting efficient recombinant AAV ("rAAV") virion production in the cell; and (4) culturing the producer cell to produce rAAV virions. The AAV expression vector, AAV helper construct and the helper virus or accessory function vector(s) can be introduced into
35 the producer cell, either simultaneously or serially, using standard transfection techniques.

1. AAV Expression Vectors

AAV expression vectors are constructed using known techniques to at least provide as operatively linked components in the direction of transcription, control elements including a transcriptional initiation region, the DNA of interest and a transcriptional termination region. The control elements are selected to be functional in a mammalian muscle cell. The resulting construct which contains the operatively linked components is bounded (5' and 3') with functional AAV ITR sequences.

The nucleotide sequences of AAV ITR regions are known. See, e.g., Kotin, R.M. (1994) *Human Gene Therapy* 5:793-801; Berns, K.I. "Parvoviridae and their Replication" in *Fundamental Virology*, 2nd Edition, (B.N. Fields and D.M. Knipe, eds.) for the AAV-2 sequence. AAV ITRs used in the vectors of the invention need not have a wild-type nucleotide sequence, and may be altered, e.g., by the insertion, deletion or substitution of nucleotides. Additionally, AAV ITRs may be derived from any of several AAV serotypes, including without limitation, AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAVX7, etc. Furthermore, 5' and 3' ITRs which flank a selected nucleotide sequence in an AAV expression vector need not necessarily be identical or derived from the same AAV serotype or isolate, so long as they function as intended, i.e., to allow for packaging of virions.

Suitable DNA molecules for use in AAV vectors will be less than about 5 kilobases (kb) in size and will include, for example, a gene that encodes a protein that is defective or missing from a recipient subject or a gene that encodes a protein having a desired biological or therapeutic effect (e.g., an antibacterial, antiviral or antitumor function).

Suitable DNA molecules include, but are not limited to, those encoding for proteins used for the treatment of endocrine, metabolic, hematologic, cardiovascular, neurologic, musculoskeletal, urologic, pulmonary and immune disorders, including such disorders as inflammatory diseases, autoimmune, chronic and infectious diseases, such as AIDS, cancer, hypercholesterolemia, insulin disorders such as diabetes, growth disorders, various blood disorders including various anemias, thalassemias and hemophilia; genetic defects such as cystic fibrosis, Gaucher's Disease, Hurler's Disease, adenosine deaminase (ADA) deficiency, emphysema, or the like.

To exemplify the invention, the gene encoding erythropoietin (EPO) can be used. EPO is a glycoprotein hormone produced in fetal liver and adult kidney which acts on progenitor cells in the bone marrow and other hematopoietic tissue to stimulate the formation of red blood cells. Genes encoding human and other mammalian EPO have been cloned, sequenced and expressed, and show a high degree of sequence homology in the coding region across species. Wen et al. (1993) *Blood* 82:1507-1516. The sequence of the gene encoding native human EPO, as well as methods of obtaining the same, are described in, e.g., U.S. Patent Nos. 4,954,437 and 4,703,008, as well as in Jacobs et al. (1985) *Nature* 313:806-810; Lin et al. (1985) *Proc. Natl. Acad. Sci. USA* 82:7580; International Publication Number WO 85/02610; and European Patent Publication Number 232,034 B1. In addition, the sequences of the genes encoding native feline, canine and porcine EPO are known and readily available (GenBank Accession Nos.: L10606; L13027; and L10607, respectively), and the sequence of the gene encoding monkey (*Macaca mulatta*) is also known and available (GenBank Accession No.: L10609). The term "EPO" as used herein refers to the native, full-length

secreted form of EPO, as well as to analogs or derivatives thereof comprising single or multiple amino acid substitutions, deletions or additions which retain EPO function or activity. In this regard, a number of small peptides have been identified which bind to and activate the receptor for EPO. Wrighton et al. (1996) *Science* 273:458-463; Livnah et al. (1996) *Science* 273:464-471. The recombinant AAV virions described herein which include a gene encoding EPO, or encoding an analog or derivative thereof having the same function, are particularly useful in the treatment of blood disorders characterized by defective red blood cell formation, such as in the treatment of anemia. Increased red blood cell production due to the production of EPO can be readily determined by an appropriate indicator, such as by comparing hematocrit measurements pre- and post-treatment, measuring increases in red blood cell count, hemoglobin concentration, or in reticulocyte counts. As described above, the EPO gene is flanked by AAV ITRs.

Alternatively, a nucleotide sequence encoding the lysosomal enzyme acid α -glucosidase (GAA) can be used. GAA functions to cleave α -1,4 and α -1,6 linkages of lysosomal glycogen to release monosaccharides. The sequence of the gene encoding human GAA, as well as methods of obtaining the same, have been previously described (GenBank Accession Numbers: M34424 and Y00839; Martiniuk et al. (1990) *DNA Cell Biol.* 9:85-94; Martiniuk et al. (1986) *Proc. Natl. Acad. Sci. USA* 83:9641-9644; Hoefsloot et al. (1988) *Eur. Mol. Biol. Organ.* 7:1697-1704). Thus, the recombinant AAV virions described herein can include a nucleotide sequence encoding GAA, or encoding an analog or derivative thereof having GAA activity.

The selected nucleotide sequence, such as EPO or another gene of interest, is operably linked to

control elements that direct the transcription or expression thereof in the subject *in vivo*. Such control elements can comprise control sequences normally associated with the selected gene.

5 Alternatively, heterologous control sequences can be employed. Useful heterologous control sequences generally include those derived from sequences encoding mammalian or viral genes. Examples include, but are not limited to, the SV40 early promoter; mouse
10 mammary tumor virus LTR promoter; adenovirus major late promoter (Ad MLP); herpes simplex virus (HSV) promoters; a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter region (CMVIE); a rous sarcoma virus (RSV) promoter; synthetic
15 promoters; hybrid promoters; and the like. In addition, sequences derived from nonviral genes, such as the murine metallothionein gene, will also find use herein. Such promoter sequences are commercially available from, e.g., Stratagene (San Diego, CA).

20 For purposes of the present invention, control elements, such as muscle-specific and inducible promoters, enhancers and the like, will be of particular use. Such control elements include, but are not limited to, those derived from the actin and
25 myosin gene families, such as from the myoD gene family (Weintraub et al. (1991) *Science* 251:761-766); the myocyte-specific enhancer binding factor MEF-2 (Cserjesi and Olson (1991) *Mol. Cell Biol.* 11:4854-4862); control elements derived from the human
30 skeletal actin gene (Muscat et al. (1987) *Mol. Cell Biol.* 7:4089-4099) and the cardiac actin gene; muscle creatine kinase sequence elements (Johnson et al. (1989) *Mol. Cell Biol.* 9:3393-3399) and the murine creatine kinase enhancer (mCK) element; control
35 elements derived from the skeletal fast-twitch troponin C gene, the slow-twitch cardiac troponin C gene and the slow-twitch troponin I gene; hypoxia-

inducible nuclear factors (Semenza et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:5680-5684; Semenza et al. *J. Biol. Chem.* 269:23757-23763); steroid-inducible elements and promoters, such as the glucocorticoid response element (GRE) (Mader and White (1993) *Proc. Natl. Acad. Sci. USA* 90:5603-5607); the fusion consensus element for RU486 induction; elements that provide for tetracycline regulated gene expression (Dhawan et al. (1995) *Somat. Cell. Mol. Genet.* 21:233-240; Shockett et al. (1995) *Proc. Natl. Acad. Sci. USA* 92:6522-6526; and inducible, synthetic humanized promoters (Rivera et al. (1996) *Nature Med.* 2:1028-1032).

These and other regulatory elements can be tested for potential *in vivo* efficacy using the *in vitro* myoblast model, which mimics quiescent *in vivo* muscle physiology, described in the examples below.

The AAV expression vector which harbors the DNA molecule of interest bounded by AAV ITRs, can be constructed by directly inserting the selected sequence(s) into an AAV genome which has had the major AAV open reading frames ("ORFs") excised therefrom. Other portions of the AAV genome can also be deleted, so long as a sufficient portion of the ITRs remain to allow for replication and packaging functions. Such constructs can be designed using techniques well known in the art. See, e.g., U.S. Patent Nos. 5,173,414 and 5,139,941; International Publication Nos. WO 92/01070 (published 23 January 1992) and WO 93/03769 (published 4 March 1993); Lebkowski et al. (1988) *Molec. Cell. Biol.* 8:3988-3996; Vincent et al. (1990) *Vaccines* 90 (Cold Spring Harbor Laboratory Press); Carter, B.J. (1992) *Current Opinion in Biotechnology* 3:533-539; Muzyczka, N. (1992) *Current Topics in Microbiol. and Immunol.* 158:97-129; Kotin, R.M. (1994) *Human Gene Therapy* 5:793-801; Shelling and Smith (1994) *Gene*

Therapy 1:165-169; and Zhou et al. (1994) *J. Exp. Med.* 179:1867-1875.

Alternatively, AAV ITRs can be excised from the viral genome or from an AAV vector containing the same and fused 5' and 3' of a selected nucleic acid construct that is present in another vector using standard ligation techniques, such as those described in Sambrook et al., *supra*. For example, ligations can be accomplished in 20 mM Tris-Cl pH 7.5, 10 mM MgCl₂, 10 mM DTT, 33 µg/ml BSA, 10 mM-50 mM NaCl, and either 40 µM ATP, 0.01-0.02 (Weiss) units T4 DNA ligase at 0°C (for "sticky end" ligation) or 1 mM ATP, 0.3-0.6 (Weiss) units T4 DNA ligase at 14°C (for "blunt end" ligation). Intermolecular "sticky end" ligations are usually performed at 30-100 µg/ml total DNA concentrations (5-100 nM total end concentration). AAV vectors which contain ITRs have been described in, e.g., U.S. Patent no. 5,139,941. In particular, several AAV vectors are described therein which are available from the American Type Culture Collection ("ATCC") under Accession Numbers 53222, 53223, 53224, 53225 and 53226.

Additionally, chimeric genes can be produced synthetically to include AAV ITR sequences arranged 5' and 3' of one or more selected nucleic acid sequences. Preferred codons for expression of the chimeric gene sequence in mammalian muscle cells can be used. The complete chimeric sequence is assembled from overlapping oligonucleotides prepared by standard methods. See, e.g., Edge, *Nature* (1981) 292:756; Nambair et al. *Science* (1984) 223:1299; Jay et al. *J. Biol. Chem.* (1984) 259:6311.

In order to produce rAAV virions, an AAV expression vector is introduced into a suitable producer cell using known techniques, such as by transfection. A number of transfection techniques are generally known in the art. See, e.g., Graham et al.

(1973) *Virology*, 52:456, Sambrook et al. (1989) *Molecular Cloning, a laboratory manual*, Cold Spring Harbor Laboratories, New York, Davis et al. (1986) *Basic Methods in Molecular Biology*, Elsevier, and Chu et al. (1981) *Gene* 13:197. Particularly suitable transfection methods include calcium phosphate co-precipitation (Graham et al. (1973) *Virol.* 52:456-467), direct micro-injection into cultured cells (Capecchi, M.R. (1980) *Cell* 22:479-488),
10 electroporation (Shigekawa et al. (1988) *BioTechniques* 6:742-751), liposome mediated gene transfer (Mannino et al. (1988) *BioTechniques* 6:682-690), lipid-mediated transduction (Felgner et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:7413-7417), and nucleic acid delivery
15 using high-velocity microprojectiles (Klein et al. (1987) *Nature* 327:70-73).

For the purposes of the invention, suitable producer cells for producing rAAV virions include microorganisms, yeast cells, insect cells, and
20 mammalian cells, that can be, or have been, used as recipients of a heterologous DNA molecule. The term includes the progeny of the original cell which has been transfected. Thus, a "producer cell" as used herein generally refers to a cell which has been
25 transfected with an exogenous DNA sequence. Cells from the stable human cell line, 293 (readily available through, e.g., the American Type Culture Collection under Accession Number ATCC CRL1573) are preferred in the practice of the present invention.
30 Particularly, the human cell line 293 is a human embryonic kidney cell line that has been transformed with adenovirus type-5 DNA fragments (Graham et al. (1977) *J. Gen. Virol.* 36:59), and expresses the adenoviral E1a and E1b genes (Aiello et al. (1979) *Virology* 94:460). The 293 cell line is readily
35 transfected, and provides a particularly convenient platform in which to produce rAAV virions.

2. AAV Helper Functions

Producer cells containing the above-described AAV expression vectors must be rendered capable of providing AAV helper functions in order to replicate and encapsidate the nucleotide sequences flanked by the AAV ITRs to produce rAAV virions. AAV helper functions are generally AAV-derived coding sequences which can be expressed to provide AAV gene products that, in turn, function in *trans* for productive AAV replication. AAV helper functions are used herein to complement necessary AAV functions that are missing from the AAV expression vectors. Thus, AAV helper functions include one, or both of the major AAV ORFs, namely the *rep* and *cap* coding regions, or functional homologues thereof.

By "AAV *rep* coding region" is meant the art-recognized region of the AAV genome which encodes the replication proteins Rep 78, Rep 68, Rep 52 and Rep 40. These Rep expression products have been shown to possess many functions, including recognition, binding and nicking of the AAV origin of DNA replication, DNA helicase activity and modulation of transcription from AAV (or other heterologous) promoters. The Rep expression products are collectively required for replicating the AAV genome. For a description of the AAV *rep* coding region, see, e.g., Muzyczka, N. (1992) *Current Topics in Microbiol. and Immunol.* 158:97-129; and Kotin, R.M. (1994) *Human Gene Therapy* 5:793-801. Suitable homologues of the AAV *rep* coding region include the human herpesvirus 6 (HHV-6) *rep* gene which is also known to mediate AAV-2 DNA replication (Thomson et al. (1994) *Virology* 204:304-311).

By "AAV *cap* coding region" is meant the art-recognized region of the AAV genome which encodes the capsid proteins VP1, VP2, and VP3, or functional homologues thereof. These *cap* expression products are the capsid proteins which are collectively required

for packaging the viral genome. For a description of the AAV *cap* coding region, see, e.g., Muzyczka, N. and Kotin, R.M. (*supra*).

AAV helper functions are introduced into the producer cell by transfecting the cell with an AAV helper construct either prior to, or concurrently with, the transfection of the AAV expression vector. AAV helper constructs are thus used to provide at least transient expression of AAV *rep* and/or *cap* genes to complement missing AAV functions that are necessary for productive AAV infection. AAV helper constructs lack AAV ITRs and can neither replicate nor package themselves.

These constructs can be in the form of a plasmid, phage, transposon, cosmid, virus, or virion. A number of AAV helper constructs have been described, such as the commonly used plasmids pAAV/Ad and pIM29+45 which encode both Rep and Cap expression products. See, e.g., Samulski et al. (1989) *J. Virol.* 63:3822-3828; and McCarty et al. (1991) *J. Virol.* 65:2936-2945. A number of other vectors have been described which encode Rep and/or Cap expression products. See, e.g., U.S. Patent No. 5,139,941.

Both AAV expression vectors and AAV helper constructs can be constructed to contain one or more optional selectable markers. Suitable markers include genes which confer antibiotic resistance or sensitivity to, impart color to, or change the antigenic characteristics of those cells which have been transfected with a nucleic acid construct containing the selectable marker when the cells are grown in an appropriate selective medium. Several selectable marker genes that are useful in the practice of the invention include the hygromycin B resistance gene (encoding Aminoglycoside phosphotransferase (APH)) that allows selection in mammalian cells by conferring resistance to G418

(available from Sigma, St. Louis, Mo.). Other suitable markers are known to those of skill in the art.

5 3. Accessory Functions

 The producer cell must also be rendered capable of providing non AAV derived functions, or "accessory functions," in order to produce rAAV virions. Accessory functions are non AAV derived
10 viral and/or cellular functions upon which AAV is dependent for its replication. Thus, accessory functions include at least those non AAV proteins and RNAs that are required in AAV replication, including those involved in activation of AAV gene
15 transcription, stage specific AAV mRNA splicing, AAV DNA replication, synthesis of Cap expression products and AAV capsid assembly. Viral-based accessory functions can be derived from any of the known helper viruses.

20 Particularly, accessory functions can be introduced into and then expressed in producer cells using methods known to those of skill in the art. Commonly, accessory functions are provided by infection of the producer cells with an unrelated
25 helper virus. A number of suitable helper viruses are known, including adenoviruses; herpesviruses such as herpes simplex virus types 1 and 2; and vaccinia viruses. Nonviral accessory functions will also find use herein, such as those provided by cell
30 synchronization using any of various known agents. See, e.g., Buller et al. (1981) *J. Virol.* 40:241-247; McPherson et al. (1985) *Virology* 147:217-222; Schlehofer et al. (1986) *Virology* 152:110-117.

 Alternatively, accessory functions can be
35 provided using an accessory function vector. Accessory function vectors include nucleotide sequences that provide one or more accessory

functions. An accessory function vector is capable of being introduced into a suitable producer cell in order to support efficient AAV virion production in the cell. Accessory function vectors can be in the form of a plasmid, phage, transposon or cosmid. Accessory vectors can also be in the form of one or more linearized DNA or RNA fragments which, when associated with the appropriate control elements and enzymes, can be transcribed or expressed in a producer cell to provide accessory functions.

Nucleic acid sequences providing the accessory functions can be obtained from natural sources, such as from the genome of an adenovirus particle, or constructed using recombinant or synthetic methods known in the art. In this regard, adenovirus-derived accessory functions have been widely studied, and a number of adenovirus genes involved in accessory functions have been identified and partially characterized. See, e.g., Carter, B.J. (1990) "Adeno-Associated Virus Helper Functions," in *CRC Handbook of Parvoviruses*, vol. I (P. Tijssen, ed.), and Muzyczka, N. (1992) *Curr. Topics. Microbiol. and Immun.* 158:97-129. Specifically, early adenoviral gene regions E1a, E2a, E4, VAI RNA and, possibly, E1b are thought to participate in the accessory process. Janik et al. (1981) *Proc. Natl. Acad. Sci. USA* 78:1925-1929. Herpesvirus-derived accessory functions have been described. See, e.g., Young et al. (1979) *Prog. Med. Virol.* 25:113. Vaccinia virus-derived accessory functions have also been described. See, e.g., Carter, B.J. (1990), *supra.*, Schlehofer et al. (1986) *Virology* 152:110-117.

As a consequence of the infection of the producer cell with a helper virus, or transfection of the producer cell with an accessory function vector, accessory functions are expressed which transactivate the AAV helper construct to produce AAV Rep and/or Cap

proteins. The Rep expression products excise the recombinant DNA (including the DNA of interest) from the AAV expression vector. The Rep proteins also serve to duplicate the AAV genome. The expressed Cap
5 proteins assemble into capsids, and the recombinant AAV genome is packaged into the capsids. Thus, productive AAV replication ensues, and the DNA is packaged into rAAV virions.

Following recombinant AAV replication, rAAV
10 virions can be purified from the producer cell using a variety of conventional purification methods, such as CsCl gradients. Further, if infection is employed to express the accessory functions, residual helper virus can be inactivated, using known methods. For example,
15 adenovirus can be inactivated by heating to temperatures of approximately 60°C for, e.g., 20 minutes or more. This treatment effectively inactivates only the helper virus since AAV is extremely heat stable while the helper adenovirus is
20 heat labile.

The resulting rAAV virions are then ready for use for DNA delivery, such as in gene therapy applications, for the production of transgenic animals, in vaccination, and particularly for the
25 delivery of genes to a variety of muscle cell types.

4. In vitro and In vivo Delivery of rAAV Virions

Generally, rAAV virions are introduced into a muscle cell using either *in vivo* or *in vitro*
30 transduction techniques. If transduced *in vitro*, the desired recipient muscle cell will be removed from the subject, transduced with rAAV virions and reintroduced into the subject. Alternatively, syngeneic or xenogeneic muscle cells can be used where those cells
35 will not generate an inappropriate immune response in the subject.

Suitable methods for the delivery and introduction of transduced cells into a subject have been described. For example, cells can be transduced *in vitro* by combining recombinant AAV virions with muscle cells e.g., in appropriate media, and screening for those cells harboring the DNA of interest using conventional techniques such as Southern blots and/or PCR, or by using selectable markers. Transduced cells can then be formulated into pharmaceutical compositions, described more fully below, and the composition introduced into the subject by various techniques, such as by intramuscular, intravenous, subcutaneous and intraperitoneal injection, or by injection into smooth and cardiac muscle, using e.g., a catheter.

For *in vivo* delivery, the rAAV virions will be formulated into pharmaceutical compositions and will generally be administered parenterally, e.g., by intramuscular injection directly into skeletal or cardiac muscle.

Pharmaceutical compositions will comprise sufficient genetic material to produce a therapeutically effective amount of the protein of interest, i.e., an amount sufficient to reduce or ameliorate symptoms of the disease state in question or an amount sufficient to confer the desired benefit. The pharmaceutical compositions will also contain a pharmaceutically acceptable excipient. Such excipients include any pharmaceutical agent that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Pharmaceutically acceptable excipients include, but are not limited to, liquids such as water, saline, glycerol and ethanol. Pharmaceutically acceptable salts can be included therein, for example, mineral acid salts such as hydrochlorides, hydrobromides,

phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. A thorough discussion of pharmaceutically acceptable excipients is available in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J. 1991).

Appropriate doses will depend on the mammal being treated (e.g., human or nonhuman primate or other mammal), age and general condition of the subject to be treated, the severity of the condition being treated, the particular therapeutic protein in question, its mode of administration, among other factors. An appropriate effective amount can be readily determined by one of skill in the art.

Thus, a "therapeutically effective amount" will fall in a relatively broad range that can be determined through clinical trials. For example, for *in vivo* injection, i.e., injection directly to skeletal or cardiac muscle, a therapeutically effective dose will be on the order of from about 10^6 to 10^{15} of the rAAV virions, more preferably 10^8 to 10^{14} rAAV virions. For *in vitro* transduction, an effective amount of rAAV virions to be delivered to muscle cells will be on the order of 10^8 to 10^{13} of the rAAV virions. The amount of transduced cells in the pharmaceutical compositions will be from about 10^4 to 10^{10} muscle cells, more preferably 10^5 to 10^8 muscle cells. When the transduced cells are introduced to vascular smooth muscle, a lower dose may be appropriate. Other effective dosages can be readily established by one of ordinary skill in the art through routine trials establishing dose response curves.

Dosage treatment may be a single dose schedule or a multiple dose schedule. Moreover, the subject may be administered as many doses as appropriate. One of skill in the art can readily
5 determine an appropriate number of doses.

C. Experimental

Below are examples of specific embodiments for carrying out the present invention. The examples
10 are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts,
15 temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

Materials and Methods

20 Vector constructs

A. Construction of p1909adh1acZ.

Plasmid p1909adh1acZ was used as the helper construct in the following examples and was constructed from plasmid pWadh1acZ. Plasmid pWadh1acZ
25 was constructed by partially digesting plasmid pUC119 (GeneBank Reference Name: U07649, GeneBank Accession Number: U07649) with *Afl*III and *Bsp*HI, blunt-end modifying with the klenow enzyme, and then ligating to form a circular 1732 bp plasmid containing the
30 bacterial origin and the *amp* gene only (the polylinker and F1 origin was removed). The blunted and ligated *Afl*III and *Bsp*HI junction forms a unique *Nsp*I site. The 1732 bp plasmid was cut with *Nsp*I, blunt-end modified with T4 polymerase, and a 20 bp
35 *Hin*DIII-*Hin*CII fragment (blunt-end modified with the klenow enzyme) obtained from the pUC119 polylinker was ligated into the blunted *Nsp*I site of the plasmid.

The *Hind*III site from the blunted polylinker was regenerated, and then positioned adjacent to the bacterial origin of replication. The resulting plasmid was then cut at the unique *Pst*I/*Sse*8387I site, and an *Sse*8387I-*Pvu*II-*Sse*8387I oligonucleotide, having the sequence: 5'-GGCAGCTGCCTGCA-3' (SEQ ID NO.:___), was ligated therein. The remaining unique *Bsp*HI site was cut, blunt-end modified with klenow enzyme, and an *Asc*I linker oligonucleotide, having the sequence: 5'-GAAGGCGCGCCTTC-3' (SEQ ID NO.:___) was ligated therein, eliminating the *Bsp*HI site. The resulting plasmid was called pWee.

In order to create the pWadh_{lacZ} construct, a CMV_{lacZ} expression cassette (comprising a nucleotide sequence flanked 5' and 3' by AAV ITRs, containing the following elements: a CMV promoter, the hGH 1st intron, an adh_{lacZ} fragment and an SV40 early polyadenylation site) was inserted into the unique *Pvu*II site of pWee using multiple steps such that the CMV promoter was arranged proximal to the bacterial *amp* gene of pWee.

More particularly, a CMV_{lacZ} expression cassette was derived from the plasmid psub201CMV, which was constructed as follows. An oligonucleotide encoding the restriction enzyme sites: *Not*I-*Mlu*I-*Sna*BI-*Age*I-*Bst*BI-*Bss*HII-*Nco*I-*Hpa*I-*Bsp*EI-*Pml*I-*Rsr*II-*Not*I and having the following nucleotide sequence: 5'-GCGGCCGCACGCGTACGTACCGGTTCGAAGCGCGCACGGCCGACCATGGTTAACTCCGGACACGTGCGGACCGCGGCCGC-3' (SEQ ID No.:___) was synthesized and cloned into the blunt-end modified *Kas*I-*Ear*I site (partial) of pUC119 to provide a 2757 bp vector fragment. A 653 bp *Spe*I-*Sac*II fragment containing a nucleotide sequence encoding a CMV immediate early promoter was cloned into the *Sna*BI site of the 2757 bp vector fragment. Further, a 269

bp PCR-produced *Bst*BI-*Bst*BI fragment containing a nucleotide sequence encoding the hGH 1st intron which was derived using the following primers:

5'—AAAATTCTGAACCTGGGGAGAAACCAGAG—3' (SEQ ID NO.:___)

5 and 3'—aaaattcgaacaggttaagcgcccctTTG—5' (SEQ ID NO.:___), was cloned into the *Bst*BI site of the 2757 bp vector fragment, and a 135 bp *Hpa*I-*Bam*HI (blunt-end modified) fragment containing the SV40 early polyadenylation site from the pCMV- β plasmid (CLONETECH) was cloned into the *Hpa*I site of the subject vector fragment. The resulting construct was then cut with *Not*I to provide a first CMV expression cassette.

Plasmid pW1909adh_{lacZ} was constructed as follows. A 4723 bp *Spe*I-*Eco*RV fragment containing the AAV *rep* and *cap* encoding region was obtained from the plasmid pGN1909 (ATCC Accession Number 69871). The pGN1909 plasmid is a high efficiency AAV helper plasmid having AAV *rep* and *cap* genes with an AAV p5 promoter region that is arranged in the construct to be downstream from its normal position (in the wild type AAV genome) relative to the *rep* coding region. The 4723 bp fragment was blunt-end modified, and *Asc*I linkers were ligated to the blunted ends. The resultant fragment was then ligated into the unique *Asc*I site of pWadh_{lacZ} and oriented such that the AAV coding sequences were arranged proximal to the bacterial origin of replication in the construct.

Plasmid pW1909adh_{lacZ} includes the bacterial beta-galactosidase (β -gal) gene under the transcriptional control of the cytomegalovirus immediate early promoter (CMVIE).

B. Construction of pW1909EPO.

Plasmid pW1909adh_{lacZ} was modified to express human erythropoietin (EPO) by replacing the adh_{lacZ} gene with a 718 base pair *Ppu*MI-*Nco*I fragment

of human EPO cDNA (Wen et al. (1993) *Blood* 5:1507-1516) and by cloning a 2181 bp *ClaI*-*EcoRI* lacZ spacer fragment (noncoding) into the *PmlI* site of the vector.

5 C. Construction of pAAV-GAA.

A plasmid containing the human lysosomal enzyme acid α -glucosidase (GAA) coding region was constructed as follows. A 3.2 kB cDNA clone containing the coding sequence for human GAA beginning
10 207 bps downstream from the initiation codon (GenBank Accession Numbers: M34424 and Y00839; Martiniuk et al. (1990) *DNA Cell Biol.* 9:85-94) was cloned into the *EcoRI* site of Bluescript KS (Stratagene). Additional 5' sequence was generated using polymerase chain
15 reaction (PCR) with reverse-transcribed poly-A mRNA (obtained from normal human fibroblasts) as the template. The 5' primer was constructed with a *KpnI* restriction site and bps -3 to 12 of the published sequence (Martiniuk et al. (1986) *Proc. Natl. Acad. Sci. USA* 83:9641-9644; Hoefsloot et al. (1988) *Eur. Mol. Biol. Organ.* 7:1697-1704). The 3' primer was
20 synthesized from basepairs 1001 to 1018. Using *KpnI* and the unique internal *StuI* site at position 776, the PCR product was ligated to the partial cDNA to form
25 the full-length GAA-encoding plasmid. The full length cDNA was truncated at a unique *SphI* restriction site, and cloned into the expression vector p1.1c to result in the pAAV-GAA construct having the GAA coding region under transcriptional control of the CMV-IE promoter.

30 The p1.1c expression vector was constructed as follows. pUC119 was partially digested with *KasI* and *EarI*, and a 2713 bp vector fragment containing the ampicillin resistance gene, the *coli* 1 origin of replication and the M13 origin of replication, was
35 isolated, blunt end modified, and ligated to a synthetic DNA polylinker encoding the restriction enzyme sites *NotI*-*MluI*-*SnaBI*-*AgeI*-*SfuI*-*BssHII*-*EagI*-

NcoI-PmeI-BspEI-PmlI-RsrII-NotI, and having the following nucleotide sequence:

5'—GCGGCCGCACGCGTTGTTAACAACCGGTTCTGAAGCGCG

CAGCGGCCGACCATGGGTTTAAACTCCGGACCACGTGCGGACCGAGCGGCCGC—

5 3' (SEQ ID NO.:___). The ligation was conducted such that the *MluI* end of the polylinker was ligated to the *KasI* side of the plasmid. A 653 bp *SpeI-SacII* fragment encoding the CMV immediate-early promoter, a 269 bp PCR-produced *SfuI-SfuI* produced fragment
10 encoding the hGH 1st intron (derived using the following primers: 5'—AAAATTCGAACAGGTAAGCGCCCCTTTG—3' (SEQ ID NO.:___) and

3'—AAAATTCGAACCTGGGGAGAAACCAGAG—5' (SEQ ID NO.:___)),

a 183 bp *BssHII-BssHII* polylinker fragment from
15 pBluescript II SK-, and a 135 bp *HpaI-BamHI* (blunted) fragment containing the SV40 early polyadenylation site from pCMV- β (Stratagene), were cloned into the *SnaBI*, *SfuI*, *BssHII*, and *PmeI* sites, respectively, of the aforementioned plasmid. The orientation of the
20 polylinker relative to the intron and polyadenylation site was intron-polylinker (5'*SacI*-3'*KpnI*)-polyadenylation site. The polylinker was further modified by removing the 88 bp *SacI-XhoI* polylinker fragment and replacing it with the following synthetic
25 *SacI* to *XhoI* fragment encoding the restriction enzyme sites *SacI-ClaI-EcoRI-SmaI-BamHI-XbaI-SalI-PstI-BstXI-EcoRV-BstXI-olmeganuclease-HinDIII-XhoI*, having the following nucleotide sequence:

5'—GAGCTCAATCGATTGAATCCCCGGGGATCCTCTAGAGTCGACCTGCAGCC

30 ACTGTGTTGGATATCCAACACACTGGTAGGGATAACAGGGTAATCTCGAG—3' (SEQ ID NO.:___).

Viruses and Cell Lines

35 Adenovirus type 2 (Ad2), available from the American Type Culture Collection, ATCC, Catalogue Number VR846, was used as helper virus to encapsidate vectors.

The human 293 cell line (Graham et al. (1977) *J. Gen. Virol.* 36:59-72, available from the ATCC under Accession no. CRL1573), which has adenovirus Ela and Elb genes stably integrated in its genome, was cultured in complete Dulbecco's modified Eagle's media (DMEM; Bio-Whittaker, Walkersville, MD) containing 4.5 g/L glucose, 10% heat-inactivated fetal bovine serum (FBS; Hyclone, Logan, Utah), 2 mM glutamine, and 50 units/mL penicillin and 50 µg/mL streptomycin.

The C2C12 murine myoblast cell line, available from the ATCC, Catalogue Number CRL1772, was cultured in DMEM with 20% fetal calf serum (FCS), 1% chick embryo extract and 5 µg/mL gentamicin.

Fetal human skeletal myoblasts (Clonetics) were cultured in Hams F-12 human growth medium, containing 20% FCS and 5 µg/mL gentamicin.

The above cell lines were incubated at 37 °C in 5% CO₂, and were routinely tested and found free of mycoplasma contamination.

Production of Recombinant AAV Virions

Recombinant AAV virions were produced in human 293 cells as follows. Subconfluent 293 cells were cotransfected by standard calcium phosphate precipitation (Wigler et al. (1979) *Proc. Natl. Acad. Sci USA* 76:1373-1376) with one of the AAV vector/helper plasmid constructs, pW1909adhLacZ or pW1909EPO; or with pAAV-GAA and the pW1909 helper plasmid. After 6 hours, the transfected cells were infected with Ad2 in fresh medium at a multiplicity of infection (MOI) of 2, and incubated at 37 °C in 5% CO₂ for 70 hours prior to harvest. Pelleted cells were lysed in Tris buffer (10 mM Tris, 150 mM NaCl, pH 8.0) by three cycles of freeze-thaw. The lysate was clarified of cell debris by centrifugation at 12,000 X g, and the crude-cell lysate was layered onto a cesium

chloride cushion for isopyknic gradient centrifugation. Recombinant AAV virions (rAAV-LacZ, rAAV-hEPO, or rAAV-hGAA virions) were extracted from the resulting gradient by isolating the fractions with an average density of approximately 1.38 g/mL, resuspended in Hepes buffered saline (HBS) containing 50 mM Hepes (pH 7.4) and 150 mM NaCl. The preparations were then heated at 56 °C for approximately 1 hour to inactivate Ad2.

10

Assay of rAAV by Dot-blot Hybridization

Recombinant AAV virions were DNase I digested, proteinase K treated, phenol-chloroform extracted, and DNA precipitated with sodium acetate-glycogen (final concentrations = 0.3 M sodium acetate and 160 µg/mL, respectively). DNA samples were denatured (200 µL of 2X alkaline solution (0.8 M NaOH, 20 mM EDTA) added to DNA sample) for 10 minutes, then added to appropriate wells in a dot-blot apparatus, and blotted onto wet Zeta Probe membrane (BioRad), by applying suction until wells were empty. Then, 400 µL of 1X alkaline solution was added; after 5 minutes, wells were emptied by suction. The membrane was rinsed in 2X SSC (Sambrook et al., supra) for 1 min, drained, air dried on filter paper, then baked in vacuum at 80 °C for 30 min. The membrane was then prehybridized for 30 min at 65 °C with 10 mL hybridization buffer (7% SDS, 0.25 M Sodium Phosphate, pH 7.2, 1 mM EDTA). Buffer was replaced with 10 mL fresh solution, freshly boiled probe added, and hybridized overnight at 65 °C. The membrane was washed twice with 25 mL of wash-1 buffer (5% SDS, 40 mM sodium phosphate, pH 7.2, 1 mM EDTA) for 20 min at 65 °C and twice with wash-2 buffer (1% SDS, 40 mM sodium phosphate, pH 7.2, 1 mM EDTA). The membrane was wrapped in plastic film, exposed to radiographic film, and appropriate dots excised from the membrane

35

to determine radioactivity by scintillation counting, and quantitated by comparison with standards. Titers of rAAV virion were routinely in the range of approximately 10^{13} genomes/mL.

5

Assay for Contaminating Helper Adenovirus

Contaminating infectious adenovirus was assayed as follows. Samples from the purified rAAV virion stocks were added to 50% confluent 293 cells (cultured in 12 well dishes at 1×10^5 cells/well), and the cultures were passaged for 30 days (e.g., the cultures were split 1 to 5, every 3 days) or until the culture exhibited 100% cytopathic effect (CPE) due to adenovirus infection. Cultures were examined daily for CPE, and the day upon which each experimental culture showed 100% CPE was noted. Reference 293 cell cultures infected with a range of known amounts of adenovirus type-2 (from 0 to 1×10^7 plaque forming units (pfu)/culture) were also prepared and treated in the same manner. A standard curve was then prepared from the data obtained from the reference cultures, where the adenovirus pfu number was plotted against the day of 100% CPE. The titer of infectious adenovirus type-2 in each experimental culture was then readily obtained as determined from the standard curve. The limit of detection of the assay was 100 pfu/mL. The presence of wild-type AAV contamination, analyzed by dot-blot hybridization, was approximately 7 logs lower than recombinant virion concentration.

30

Differentiation of Myoblasts

C2C12 myoblasts were transduced either while actively dividing, or as a differentiated cell culture. Differentiation was induced by placing subconfluent myoblasts in murine differentiation medium (DMEM containing 2% horse serum and standard

35

concentrations of glutamine and penicillin-streptomycin) for an interval of four days prior to transduction in order to induce myoblast fusion and formation of differentiated myotubes.

5 Fetal human skeletal myoblasts were differentiated in human differentiation medium (DMEM containing 10% horse serum and 5 μ g/mL gentamicin). Verification of differentiation was performed by microscopic analysis to determine the presence of
10 multinucleated myotubes in culture.

Example 1

Expression of rAAV-LacZ in Terminally Differentiated Adult Rat Cardiomyocytes

15 The ability of recombinant AAV virions to transduce terminally differentiated adult cardiomyocytes was established *in vitro*. Cardiomyocytes were harvested by coronary perfusion with collagenase of adult rat hearts (Fischer 344,
20 Harlan Sprague Dawley, Indianapolis, IN). Cardiomyocytes were grown on laminin-coated glass coverslips and exposed to rAAV-LacZ virions for 4 hours. After 72 hours, the cells were stained for β -galactosidase activity. AAV expression was detected
25 by blue staining of the binucleated cells. These studies demonstrated the ability of rAAV virions to transduce terminally differentiated cells. The transduction efficiency *in vitro* was 30% of adult cells at a multiplicity of infection (MOI) of 10^4
30 genomes per cell.

Example 2

Stability of rAAV-LacZ Expression In Vivo

35 Adult Fischer rats were used to analyze expression of transgenes *in vivo*. Incremental doses of rAAV-LacZ virions were injected into the left ventricular apex of the heart using either a

subxyphoid or lateral thoracotomy approach. More particularly, experimental animals were anesthetized with Metofane followed by a subxyphoid incision to expose the diaphragmatic surface of the heart. Apical
5 cardiac injections were performed with a glass micropipette. Recombinant virion was diluted in normal saline and injected at a volume of 20-50 μ L.

At varying times post-injection, hearts were harvested and examined for β -galactosidase production
10 and for the presence of infiltrating mononuclear cells. For 5-Bromo-4-chloro-3-indolyl β -D-galactoside histochemical determination, frozen sections (6 μ m) were fixed in 0.5% glutaraldehyde and stained for β -galactosidase activity as described (Sanes et al.
15 (1986) "Use of Recombinant Retrovirus to Study Post-Implantation Cell Lineage in Mouse Embryos," *EMBO J* 5:3133-3142). Paraffin sections (5 μ m) were stained with hematoxylin/eosin. Sections were examined for infiltrating mononuclear cells.

20 The above-described histochemical studies showed greater than 50% transduction of cardiomyocytes in the region of injection at each time point examined. Further, there was no inflammatory cell infiltrate noted during the course of analysis. β -
25 galactosidase staining was observed to persist in cardiac muscle for at least two months following gene transfer.

Example 3

30 In vivo Transduction of Murine Skeletal Muscle using rAAV-LacZ Virions

Recombinant AAV-LacZ virions were injected into muscle tissue of mice, and transduction assessed by β -gal activity. Particularly, *in vivo* transduction
35 was performed by intramuscular (IM) injection of recombinant AAV virions into the skeletal muscle of healthy 6-8 week old Balb/c mice (Jackson

Laboratories, Bar Harbor, ME, Simonsen Laboratories, Gilroy, CA, or Harlan Laboratories) under either Metofane (Pitman-Moore, Mundelein, IL) or ketamine-xylazine anesthesia. The mid-portion of each tibialis anterior muscle was exposed via a 1 cm incision. Injections into the tibialis anterior were carried out using a micro-capillary tube attached to a Hamilton syringe to administer the following formulations at a depth of 2 mm: phosphate-buffered saline (PBS) alone (negative control); or PBS containing either rAAV-LACZ virions or pW1909adh_{lacZ} plasmids.

Tissue samples of tibialis anterior muscle, forelimb muscle, heart, brain and liver were obtained for analysis of β -galactosidase expression. One tibialis anterior muscle from each animal was processed for cross-sectional β -galactosidase analysis, and total β -galactosidase was determined from a crude homogenate of the other muscle using a chemiluminescent assay.

For histochemical detection of β -galactosidase, muscle samples were snap-frozen in dry ice-cooled isopentane, followed by serial transverse sectioning (10 μ m) and processing according to previously described methods (Sanes et al. (1986) *EMBO J* 5:3133-3142). The cross-sectional area of the tibialis anterior expressing β -galactosidase was determined as follows: after counter-staining with nuclear fast red (Vector Labs), the X-gal stained tissue was digitally photographed and the cross-sectional area of stored images was determined using NIH Image software.

The GALACTO-LIGHT™ (Tropix, Bedford, MA) chemiluminescent reporter assay kit was used to detect total β -galactosidase activity in the entire tibialis anterior muscle. Standard curves were prepared from known amounts of purified β -galactosidase (Sigma, St. Louis, MO) resuspended in non-transduced muscle

homogenate. β -galactosidase activity is expressed as either: nanograms of β -galactosidase, normalized for the entire muscle, minus background activity; or in terms of relative light units (RLU) as quantified by luminometer. Forelimb muscle, cardiac muscle, brain tissue and liver samples were assayed in an identical fashion.

10 A. Time course of β -galactosidase expression.

A single intramuscular injection into the left and right tibialis anterior muscles (under direct vision) was used to deliver 8×10^9 rAAV-LacZ in a PBS vehicle. Four animals were injected with PBS alone. 15 Animals were sacrificed at 2, 4, 8, 12, 24 and 32 weeks after injection, and the tibialis anterior muscle was excised and analyzed for the presence of bacterial β -galactosidase (n=5 for each group) as described above.

20 Efficiency of the LacZ gene transfer was assessed by cross-sectional tissue staining and chemiluminescent assay. As can be seen in Figure 1 and in Table I below, gene expression persisted for at least 32 weeks. In addition, two weeks after 25 injection of the recombinant virions, 18% of the muscle cross-sectional area expressed β -galactosidase, while at 32 weeks, 24% of the muscle cross-sectional area expressed β -galactosidase. Negative control tibialis anterior muscle (obtained from the animals 30 injected with PBS alone) showed no background staining. Muscle β -galactosidase activity was also determined in the contralateral injected muscle. This study also revealed persistent expression for at least 32 weeks, in agreement with the cross-sectional fiber 35 analysis (Table I). Further, the observed β -galactosidase was sustained with minimal inflammatory cell infiltrate. These data demonstrate that rAAV-

LacZ virion administration into muscle results in stable expression of the transgene for at least 8 months.

5 Upon histological examination, positive
staining filled the cytoplasm of the transduced
myofibers and was observed through large contiguous
portions of the muscle. Serial transverse sections
revealed that blue staining extended throughout the
length of the muscle fiber. Diffraction-interference
10 contrast microscopy revealed a clear delineation
between positively and negatively stained myofibers
(Figure 2), suggesting that recombinant virion
delivery was limited by structural barriers such as
epimyseal or perimyseal connective tissue.
15 Homogenates prepared from brain, heart, liver, and
forelimb muscle displayed no β -galactosidase activity
when compared with the background activity of the
negative control animals.

20

25

30

35

Table I
Time Course of β -galactosidase Expression
Following Single Injection with rAAV-LacZ.

Time (weeks)	β -galactosidase expression (ng/muscle)	Percent cross- sectional area expressing β - galactosidase (%)
2	1441 \pm 458	18 \pm 6
4	951 \pm 176	20 \pm 4
8	839 \pm 436	24 \pm 3
12	1878 \pm 521	29 \pm 5
24	2579 \pm 1165	22 \pm 3
32	1242 \pm 484	24 \pm 3

The left and right tibialis anterior muscles were injected with 8×10^9 rAAV-lacZ. One member of the pair of injected muscles was processed for β -galactosidase expression ($n=5 \pm$ SEM). The other muscle was processed for histochemical detection of β -galactosidase and determination of the cross-sectional area of the tibialis anterior expressing β -galactosidase. Mean cross-sectional areas \pm SEM are shown.

B. Dose-response assay.

To determine the effective dose range for rAAV-LacZ *in vivo*, recombinant virions were injected into the tibialis anterior muscle of 6-8 week old Balb/c mice, and transduction assessed by β -galactosidase activity as measured by GLACTO-LIGHT™ relative light units (RLU). As can be seen in Figure 3, at two weeks post-injection, the observed RLU ranged from approximately 0.2×10^7 RLU/muscle (injected with 8×10^8 rAAV-LacZ) to approximately 1.1×10^9 RLU/muscle (injected with 3.6×10^{11} rAAV-LacZ).

The levels of expression of β -galactosidase measured in RLU correspond to the percentage of β -galactosidase-positive muscle fibers on cross-sectional analysis. For example, 0.2×10^7 RLU corresponds to approximately 1% β -galactosidase

positive muscle fibers and 1.1×10^9 RLU corresponds to approximately 60% β -galactosidase positive muscle fibers.

5 C. Comparison of β -galactosidase expression efficiency.

 A comparison of β -galactosidase expression efficiency obtained by *in vivo* transduction of mice using either rAAV-LacZ virions, or plasmid DNA
10 containing the same LacZ expression cassette (pW1909adhLacZ) was carried out as follows. Either 8×10^9 rAAV-LacZ, or 100 μ g of pW1909adhLacZ, was injected into the tibialis anterior muscle of 6-8 week old Balb/c mice. Two weeks post-injection, β -
15 galactosidase activity was assessed using the GALACTO-LIGHT™ chemiluminescent reporter assay kit, as described above. Administration of the recombinant virions resulted in 1441 ng β -galactosidase/muscle (n=5), while administration of 100 μ g of the plasmid
20 DNA, a typical *in vivo* plasmid DNA dosage (Whalen et al. (1995) *Hum. Gene Ther.* 4:151-159), resulted in 12 ng β -galactosidase/muscle (n=4). This dosage of pW1909adhLacZ plasmid DNA is equivalent to 2.2×10^{13} single stranded genomes, demonstrating that gene
25 delivery by the recombinant virions was substantially more efficient than delivery of an equal molar quantity of vector DNA.

30

35

Example 4In vitro Transduction of Murine
Myotubes and Myoblasts

In order to determine if differentiated
5 cultured muscle cells are appropriate targets for
recombinant AAV virion transduction, and to assess the
ability of such cells to express a transduced gene,
the following study was carried out. Murine C2C12
cells were selected since these cells have been
10 extensively studied as a model for mammalian
myogenesis (Blau et al. (1993) *Trends Genet.* 9:269-
274), and can be induced to differentiate by growth in
reduced serum medium.

In the study, C2C12 myoblasts (dividing
15 cells) were seeded in cell culture plates at a density
of 2×10^4 cells/cm², maintained in growth media (GM)
until confluent, split, and then either cultured in GM
or cultured for 5 days in murine DM. Differentiation
was verified by the microscopic presence of
20 multinucleate myotubes, representing fused myoblasts
(differentiated C2C12 cells).

The C2C12 myotubes and myoblasts were
transduced in culture with purified rAAV-hEPO virions
at a MOI of 10^5 in OptiMEM (Gibco BRL). In the
25 myotube cultures, DM was added after virion
adsorption. The culture media of the transduced cells
was changed 24 hours prior to collection of
supernatants at 3, 8 and 14 days following
transduction. Secretion of hEPO was assessed by ELISA
30 using the human erythropoietin Quantikine IVD kit
(available from R and D Systems, Minneapolis, MN)
according to manufacturer's recommendations.

The results of the study show that hEPO is
secreted from both the transduced myotubes and
35 myoblasts. The levels of hEPO secretion increased in
the myotubes over the first seven days post-
transduction (Figure 4). As can be seen by reference

to Figure 5, a dose-dependent increase in the secretion of hEPO was also observed in the transduced C2C12 myotubes. Eight days post-transduction of the myotubes, hEPO levels peaked at >3400 mU/mL. These data demonstrate that transduction with rAAV-hEPO of both myotubes or myoblasts results in hEPO secretion by the transduced cells, and that in short-term myotube cultures, hEPO is synthesized and secreted in a dose-dependent manner.

10

Example 5

In vitro Transduction of Human Myotubes Using rAAV-hEPO Virions

To determine if differentiated primary human muscle cells are able to express hEPO following transduction with rAAV-hEPO, the following study was carried out. Primary fetal human skeletal myoblasts were seeded in cell culture plates at a density of 2×10^4 cells/cm², grown to confluence in appropriate growth media, and then cultured for 14 days in human DM. Differentiation was verified by microscopic examination for multinucleate cells. *In vitro* transduction was carried out by adding purified rAAV-hEPO virions to the cultured myotubes in OptiMEM medium (Gibco BRL). DM was added to the cultures after virion adsorption. Control cultures were transduced with rAAV-LacZ.

Culture media was changed 24 hours prior to collection of supernatants at day 3, 8 and 14 post transduction. Secreted EPO levels were assayed by ELISA as described above in Example 4.

As can be seen in Figure 6, the transduced human myotubes secreted hEPO into the culture in a dose-dependent manner. No detectable EPO activity was measured in the control cultures. Secretion of EPO increased over the 14-day interval post-transduction. These data demonstrate that primary human myotubes

transduced by recombinant AAV virions are capable of expressing and secreting erythropoietin.

Example 6

5 Systemic Delivery of Human Erythropoietin In vivo
 by Intramuscular Administration of rAAV-hEPO

Recombinant AAV virions encoding hEPO were administered to adult healthy Balb/c mice *in vivo* to determine if a systemic level of hEPO can be produced, and a biological response obtained. At various time points after administration, blood was obtained from the orbital venous plexus under anesthesia. Serum hEPO levels were determined by ELISA as described above. Red cell counts were done by hemocytometer, hematocrit was determined by centrifugation of blood in micro-capillary tubes, and hemoglobin concentration was analyzed by cyanmethemoglobin assay (DMA, Arlington, TX) according to manufacturer's specifications and compared with a standard (Stanbio Laboratory, San Antonio, TX) analyzed at 570 nm on a spectrophotometer. Reticulocytes were analyzed by either new methylene blue stain, or by FACS analysis of thiazole orange stained peripheral blood samples (RETIC-COUNT®, Becton-Dickinson, Mountain View, CA); the results of data obtained by either of these methods were similar.

An initial experiment revealed that high levels of hEPO and elevated hematocrits were maintained for >100 days in mice injected IM with 6.5×10^{11} rAAV-hEPO. Next, adult female Balb/c mice were injected IM in both hind limbs with a single administration of rAAV-hEPO at dosages ranging from 3×10^9 to 3×10^{11} particles. Control animals were injected with rAAV-LacZ. The resulting serum hEPO levels were analyzed and are reported below in Table II. As can be seen, a well-defined dose-response was obtained 20, 41, 62 and 83 days post injection.

The time course of hEPO secretion by animals receiving rAAV-hEPO is depicted in Figure 7. As can be seen, serum levels of hEPO increased with time to plateau at from 6 to 8 weeks after injection.

5 The biological activity of secreted hEPO can be monitored by elevation of hematocrit in the experimental animals. A comparison of circulating hEPO levels versus hematocrit is shown in Table II. The comparison shows that hematocrit increased with
10 time and increasing recombinant virion dose. Further, stable elevation in hematocrit has been observed for up to 40 weeks in a group of experimental animals injected with rAAV-hEPO. Control animals had undetectable levels of hEPO (<2.5 mU/mL, the lower
15 limit of detection for the assay).

These results indicate that persistent and stable high-level secretion of hEPO, with a corresponding elevation in hematocrit, is established following a single IM administration of rAAV-hEPO.

20 In addition, comparison of the expression of hEPO by animals injected IM with rAAV-hEPO (3×10^{11} single-stranded genomes) and animals injected IM with the pW1909EPO plasmid (1.4×10^{13} double-stranded genomes in 100 μ g DNA) shows that the recombinant
25 virions gave rise to significantly greater levels of EPO expression. As reported in Table II, 20 days post-injection, recombinant virion-injected animals had serum levels of 445 ± 98 mU/mL, while the plasmid-injected animals had levels of 8 ± 10 mU/mL. At 41
30 days post-injection, levels in the recombinant virion-treated animals had risen to 725 ± 112 mU/mL, while the levels in the plasmid-treated animals had dropped below the level of detection. The animals receiving rAAV-hEPO exhibited approximately 60-fold more
35 circulating hEPO with 100-fold less input genomes at 20 days post-injection, or approximately 6000-fold greater secretion per genome. At 41 days post-

injection, this difference was even greater, since the plasmid expression was below the level of detection.

5

10

15

20

25

30

35

Table II
EPO Expression and Hematocrit: rAAV-hEPO Dose-Response

Dose	Days after Administration							
	20 days		41 days		62 days		83 days	
	EPO	HCT	EPO	HCT	EPO	HCT	EPO	HCT
3X10 ¹¹	445±98	74.2±1.2	725±112	82.3±1.2	769±61	86.5±1.4	723±253	88.5±0.7
1X10 ¹¹	85±14	72.8±1.5	212±23	79.5±1.7	234±75	83.2±0.2	220±51	83.2±2
3X10 ¹⁰	17±5	60.0±3.5	34±17	74.7±3.2	55±28	78.7±2.0	73±45	80.0±3
1X10 ¹⁰	3±1	52.9±1.8	11±3	61.5±1.9	12±8	68.4±4.6	15±5	70.8±8
3X10 ⁹	<2.5	49.9±1.4	<2.5	53.5±2.5	<2.5	57.0±2.4	4±4	57.5±3
i.v.	7±3	54.7±3.2	13±2.0	<64.4±5.3	10.1±0.7	70.8±8	21±10	74.6±7
Control	<2.5	48.9±1.0	<2.5	49.1±0.8	<2.5	48.1±0.7	<2.5	48.2±9
Plasmid	8±10	50±3.0	<2.5	50.2±1.0	<2.5	47.8±0.9	N.D.	N.D.

values representing means ± standard deviation (SD). EPO = serum levels of human EPO (mU/mL) in Balb/c mice; HCT = hematocrit (%); N.D. = not done; i.v. = intravenous injection with 3 x 10¹¹ rAAV-hEPO; Plasmid = injection with 100 µg plasmid DNA (1.4 x 10¹³ double-stranded plasmid molecules); Control = injection with 3 x 10¹¹ particles of rAAV-lacZ.

Example 7A Comparison of hEPO Secretion from rAAV-hEPO
Administered by IM or IV Routes

A comparison of the circulating levels of hEPO resulting from IM and IV routes of administration was analyzed to determine which method of gene delivery results in higher levels of systemic hEPO. Balb/c mice were injected with 3×10^{11} rAAV-hEPO using either the IM route as described above, or intravenously (IV) in PBS in a total volume of 50 μ L via the lateral tail vein. Serum hEPO levels were determined by ELISA using the methods described above.

As shown in Table II, hEPO levels resulting from the IV administrations were significantly lower than the group that received the virions by the IM route. In particular, at 20 days post-injection, the IM route resulted in levels of hEPO of 445 ± 98 mU/mL, while the IV route produced 7 ± 3.0 mU/mL. At 41 days post-injection, the EPO level observed with the IM route was 725 ± 112 as compared with 13 ± 2.0 mU/mL by IV, or approximately 60-fold more efficacious. These data demonstrate that the IM route of injection resulted in higher systemic levels of hEPO, and suggest that interstitial delivery in muscle results in improved transduction by the recombinant AAV virions.

Example 8In vitro and In vivo Transduction of
Muscle Cells Using rAAV-GAA Virions

Cardiomyopathy in infancy is frequently due to inherited metabolic disease. One such metabolic disease, glycogen storage disease type II (Pompe's disease) is an inherited cardiomyopathy caused by a deficiency in the lysosomal enzyme, acid α -glucosidase (GAA). GAA functions to cleave α -1,4 and α -1,6 linkages of lysosomal glycogen to release

monosaccharides. Loss of enzyme activity results in accumulation of lysosomal glycogen in striated muscle, and is characterized by lysosomal rupture, contractile apparatus disruption and glycogen infiltration.

5 Currently, no effective treatment is available.

Accordingly, the following studies were carried out to determine whether the recombinant AAV virions of the present invention can be used to obtain long-term expression of GAA in transduced muscle
10 cells.

A. In vitro transduction of human skeletal muscle cells with rAAV-hGAA virions.

Human skeletal myoblasts were seeded in cell
15 culture plates at a density of 2×10^4 cells/cm², grown to confluence in appropriate growth media, and then cultured for 14 days in human DM. Differentiation was verified by microscopic examination for multinucleate cells. In vitro transduction was carried out by
20 adding purified rAAV-hGAA virions at an MOI of 2×10^5 to the cultured myotubes in OptiMEM medium (Gibco BRL). DM was added to the cultures after virion adsorption. Transduced control cultures were established by transducing the myotubes with rAAV-LacZ
25 at the same MOI, and negative controls were established by culturing non-transduced myotubes.

Culture media was changed 24 hours prior to collection of supernatants at day 3, 8 and 14 post transduction. hGAA expression was determined by
30 enzymatic assay. Specifically, cell monolayers were harvested with 0.05% trypsin in Puck's saline A containing 0.02% ethylenediaminetetraacetic acid. After quenching the trypsin with growth media, cells were centrifuged, the cell pellet washed with PBS, and
35 resuspended in distilled water. Following three freeze-thaw cycles, the samples were microfuged at 10,000 x g. Protein in the supernatant was determined

using the Bicinchoninic acid method (Pierce) with bovine serum albumin (BSA) as the standard. GAA activity was measured using cleavage of the glycogen analog 4-methylumbelliferyl- α -D-glucoside, by a
5 modification of a previously described method (Galjaard et al. (1973) *Clin. Chim. Acta.* 49:361-375; Galjaard, H. (1973) *Pediatr. Res.* 7:56). Assays contained 30 μ g protein in 125 μ L water. Two volumes of 200 mM sodium acetate (pH 4.3) and 750 nM 4-
10 methyumbelliferyl- α -D-glucoside (from a stock solution of 200 mM in dimethylsulfoxide) were added and the samples incubated at 37°C for one hour. Reactions were stopped with 625 μ L sodium carbonate (pH 10.7). Once cleaved and alkalized, the 4-methyumbelliferyl
15 fluoresces. Measurements were made with a fluorescence spectrophotometer with excitation at 365 nm and emission at 448 nm. Assay measurements were compared against 4-methyumbelliferone (Sigma, St. Louis, MO) standards. Zero protein and zero time
20 blanks were used.

The observed GAA activity is reported in Figure 8 which demonstrates that *in vitro* transduction of the human myotubes results in high level GAA expression at day 8 and 14 post transduction.

25

B. In vivo transduction of skeletal muscle using rAAV-GAA virions.

Recombinant AAV virions encoding human GAA were administered to adult Balb/c mice *in vivo* to
30 determine if systemic levels of GAA can be produced by the transduced cells. Muscle tissue was isolated at various time points after administration, and processed for GAA activity using an enzymatic assay.

In the study, tibialis anterior muscle in
35 Balb/c mice was surgically exposed, and a single intramuscular injection into the left and right muscles (under direct vision) was used to administer

the following formulations: phosphate-buffered saline (PBS) alone (negative control); or PBS containing either 2×10^{10} rAAV-hGAA or rAAV-LacZ (for a total of 4×10^{10} virions/animal).

5 Tissue samples of tibialis anterior muscle were obtained at 1, 4 and 10 weeks following transduction. The tissue samples were prepared by homogenization in water followed by three freeze-thaw cycles. Freeze-thaw lysates were microcentrifuged,
10 and the resultant supernatant assayed for GAA activity as described above. The results of the study are depicted in Figure 9. As can be seen, stable expression of GAA in the transduced mouse muscle cells
15 recombinant AAV virions of the present invention are able to establish efficient expression of a functional lysosomal protein in transduced cells, and thus provide a therapeutic approach for the treatment of glycogen storage disease.

20 Accordingly, novel methods for transferring genes to muscle cells have been described. Although preferred embodiments of the subject invention have been described in some detail, it is understood that obvious variations can be made without departing from
25 the spirit and the scope of the invention as defined by the appended claims.

30

35

Deposits of Strains Useful in Practicing the Invention

A deposit of biologically pure cultures of the following strain was made with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland, under the provisions of the Budapest Treaty. The accession number indicated was assigned after successful viability testing, and the requisite fees were paid. Access to said cultures will be available during pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 CFR 1.14 and 35 USC 122. All restriction on availability of said cultures to the public will be irrevocably removed upon the granting of a patent based upon the application. Moreover, the designated deposits will be maintained for a period of thirty (30) years from the date of deposit, or for five (5) years after the last request for the deposit; or for the enforceable life of the U.S. patent, whichever is longer. Should a culture become nonviable or be inadvertently destroyed, or, in the case of plasmid-containing strains, lose its plasmid, it will be replaced with a viable culture(s) of the same taxonomic description.

This deposit is provided merely as a convenience to those of skill in the art, and is not an admission that a deposit is required. A license may be required to make, use, or sell the deposited materials, and no such license is hereby granted.

<u>Strain</u>	<u>Deposit Date</u>	<u>ATCC No.</u>
pGN1909	July 20, 1995	69871

Claims:

1. A method for producing a composition
useful for delivering a selected gene to a muscle cell
5 or tissue, comprising:
- (a) providing a recombinant adeno-
associated virus (AAV) virion which comprises an AAV
vector having said selected gene operably linked to
control elements capable of directing the *in vivo*
10 transcription and translation thereof; and
- (b) combining the recombinant AAV virion
with a pharmaceutically acceptable vehicle.
2. The method of claim 1, characterized in
15 that the composition is useful for delivering a
selected gene to a muscle cell or tissue derived from
skeletal muscle.
3. The method of claim 2, characterized in
20 that the muscle cell is a skeletal myoblast or a
skeletal myocyte.
4. The method of claim 1, characterized in
that the composition is useful for delivering a
25 selected gene to a muscle cell or tissue derived from
smooth muscle.
5. The method of claim 1, characterized in
that the composition is useful for delivering a
30 selected gene to a muscle cell or tissue derived from
cardiac muscle.
6. The method of claim 5, characterized in
that the muscle cell is a cardiomyocyte.
35

7. The method of any one of claims 1-6, characterized in that the selected gene encodes a therapeutic protein.

5 8. The method of claim 7, characterized in that the therapeutic protein is acid α -glucosidase.

9. The method of any one of claims 1-8, characterized in that the control elements comprise a
10 muscle-specific promoter sequence.

10. The method of any one of claims 1-8, characterized in that the control elements comprise an inducible promoter sequence.

15

11. A muscle cell or tissue transduced in vitro with a recombinant AAV virion, said virion comprising an AAV vector having a selected gene operably linked to control elements capable of
20 directing the in vivo transcription and translation of said selected gene.

12. The transduced muscle cell of claim 11, characterized in that the muscle cell is a skeletal
25 myoblast or a skeletal myocyte.

13. The transduced muscle cell of claim 11, characterized in that the muscle cell is a cardiomyocyte.

30

14. The transduced muscle cell of any one of claims 11-13, characterized in that the selected gene encodes a therapeutic protein.

35 15. The transduced muscle cell of claim 14, characterized in that the therapeutic protein is acid α -glucosidase.

16. The transduced muscle cell of any one of claims 11-15, characterized in that the control elements comprise a muscle-specific promoter sequence.

5 17. The transduced muscle cell of any one of claims 11-15, characterized in that the control elements comprise an inducible promoter sequence.

18. A method of transducing a mammalian muscle cell *in vitro*, comprising:

(a) providing a recombinant AAV virion which comprises an AAV vector having a selected gene operably linked to control elements capable of directing the *in vivo* transcription and translation of
15 said selected gene; and

(b) introducing the recombinant AAV virion into a suitable muscle cell to produce a transduced muscle cell.

20 19. The method of claim 18, characterized in that the muscle cell is derived from skeletal muscle.

20. The method of claim 19, characterized
25 in that the muscle cell is a skeletal myoblast or a skeletal myocyte.

21. The method of claim 18, characterized
in that the muscle cell is derived from smooth muscle.


30

22. The method of claim 18, characterized
in that the muscle cell is derived from cardiac muscle.

35

23. The method of claim 22, characterized
in that the muscle cell is a cardiomyocyte.

1/9


**FIG. 1**

2/9




FIG. 2


3/9

**FIG. 3**


4/9

**FIG. 4**

5/9

*FIG. 5*

6/9

**FIG. 6**

7/9




FIG. 7

8/9

In vitro Expression of GAA in Human Skeletal Muscle




FIG. 8

9/9

Long-term Expression of Human GAA in Mice




FIG. 9

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/00895

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/18 C12N15/56 C12N15/86 C12N5/10 C12N9/24
C07K14/505 A61K31/70 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BLOOD, vol. 86, no. 10, SUPPL.1, 15 November 1995, page 4006 XP000673499 PODSAKOFF, G., ET AL. : "LONG-TERM IN VIVO GENE EXPRESSION IN MUSCLE USING AAV VECTORS" see the whole document ---	1-7, 11-14, 18-20, 22,23
X	MODERN PATHOLOGY, vol. 8, no. 1, January 1995, page 178 XP000673501 KOURTIS, A.P., ET AL. : "CARDIAC GENE THERAPY WITH ADENO-ASSOCIATED VIRUS AS A MEANS OF ACHIEVING GRAFT-SPECIFIC IMMUNO-SUPPRESSION" see the whole document --- -/-	11,13, 18,22,23

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

16 May 1997

Date of mailing of the international search report

10.06.97

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Holtorf, S

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/00895

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 34670 A (CHILDRENS HOSPITAL INC) 21 December 1995 see page 9	1,2,7,9
A	--- HUMAN GENE THERAPY, vol. 6, October 1995, pages 1329-1341, XP000569718 CLARK, K.R., ET AL. : "CELL LINES FOR THE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS" see the whole document	1-23
A	--- PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 91, November 1994, pages 11557-11561, XP002030822 TRIPATHY, K.S., ET AL. : "STABLE DELIVERY OF PHYSIOLOGIC LEVELS OF RECOMBINANT ERYTHROPOIETIN TO THE SYSTEMIC CIRCULATION BY INTRAMUSCULAR INJECTION OF REPLICATION-DEFECTIVE ADENOVIRUS" see the whole document	1-23
A	--- TRENDS IN GENETICS, vol. 9, no. 8, 1993, pages 269-274, XP002030823 BLAU, H.M., ET AL. : "MYOBLASTS IN PATTERN FORMATION AND GENE THERAPY" see the whole document -----	1-23

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/00895

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9534670 A	21-12-95	AU 3124395 A	05-01-96
		CA 2192215 A	21-12-95
		EP 0764213 A	26-03-97



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/18, 15/56, 15/86, 5/10, 9/24, C07K 14/505, A61K 31/70, 48/00		A1	(11) International Publication Number: WO 97/26337 (43) International Publication Date: 24 July 1997 (24.07.97)
(21) International Application Number: PCT/US97/00895 (22) International Filing Date: 17 January 1997 (17.01.97) (30) Priority Data: 08/588,355 18 January 1996 (18.01.96) US 08/784,757 16 January 1997 (16.01.97) US		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>With amended claims.</i> Date of publication of the amended claims: 2 October 1997 (02.10.97)	
(71) Applicants: AVIGEN, INC. [US/US]; Suite 1000, 1201 Harbor Bay Parkway, Alameda, CA 94501 (US). JOHNS HOPKINS UNIVERSITY [US/US]; 720 Rutland Avenue, Baltimore, MD 21205 (US). (72) Inventors: PODSAKOFF, Gregory, M.; 2832 Teal Drive, Fullerton, CA 92635 (US). KESSLER, Paul, D.; 7907 Ellenham Avenue, Baltimore, MD 21204 (US). BYRNE, Barry, J.; 814 Chumleigh Road, Baltimore, MD 21212 (US). KURTZMAN, Gary, J.; 24 Campbell Lane, Menlo Park, CA 94025 (US). (74) Agents: McCracken, Thomas, P. et al.; Robins & Associates, Suite 200, 90 Middlefield Road, Menlo Park, CA 94025 (US).			

(54) Title: METHODS FOR DELIVERING DNA TO MUSCLE CELLS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VIRIONS

(57) Abstract

The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, *in vivo* injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the *in vitro* transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for *in vivo* secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

AMENDED CLAIMS

[received by the International Bureau on 10 August 1997 (10.08.97);
original claims 1-23 replaced by new claims 1-22 (4 pages)]

1. A method for producing a composition
useful for delivering a selected gene to a smooth muscle
5 cell or to smooth muscle tissue, said method comprising:

(a) providing a recombinant adeno-associated
virus (AAV) virion which comprises an AAV vector having
the selected gene operably linked to control elements
capable of directing the *in vivo* transcription and
10 translation thereof; and

(b) combining the recombinant AAV virion with
a pharmaceutically acceptable vehicle.

2. The method of claim 1, characterized in
15 that the selected gene encodes a therapeutic protein.

3. The method of claim 1 or 2, characterized
in that the control elements comprise a muscle-specific
promoter sequence.
20

4. The method of claim 1 or 2, characterized
in that the control elements comprise an inducible
promoter sequence.

25 5. A smooth muscle cell transduced with a
recombinant AAV virion, said virion comprising an AAV
vector having a selected gene operably linked to control
elements capable of directing the *in vivo* transcription
and translation of said selected gene.
30

6. The transduced muscle cell of claim 5,
characterized in that the selected gene encodes a
therapeutic protein.
35

7. The transduced muscle cell of claim 5 or 6, characterized in that the control elements comprise a muscle-specific promoter sequence.

5 8. The transduced muscle cell of claim 5 or 6, characterized in that the control elements comprise an inducible promoter sequence.

9. A method of transducing a mammalian smooth muscle cell, said method comprising:

10 (a) providing a recombinant AAV virion which comprises an AAV vector having a selected gene operably linked to control elements capable of directing the *in vivo* transcription and translation of said selected gene;
15 and

(b) introducing the recombinant AAV virion into a suitable smooth muscle cell to produce a transduced muscle cell.

20 10. A method for producing a composition useful for delivering to a muscle cell or muscle tissue a gene encoding acid α -glucosidase, said method comprising:

(a) providing a recombinant adeno-associated virus (AAV) virion which comprises an AAV vector having
25 said gene operably linked to control elements capable of directing the *in vivo* transcription and translation thereof; and

(b) combining the recombinant AAV virion with a pharmaceutically acceptable vehicle.

30

11. The method of claim 10, characterized in that the control elements comprise a muscle-specific promoter sequence.

35

12. The method of claim 10, characterized in that the control elements comprise an inducible promoter sequence.

5 13. The method of claim 10, characterized in that the composition is useful for delivering a selected gene to a muscle cell or tissue derived from skeletal muscle.

10 14. The method of claim 13, characterized in that the muscle cell is a skeletal myoblast or a skeletal myocyte.

15 15. The method of claim 10, characterized in that the composition is useful for delivering a selected gene to a muscle cell or tissue derived from smooth muscle.

20 16. The method of claim 10, characterized in that the composition is useful for delivering a selected gene to a muscle cell or tissue derived from cardiac muscle.

25 17. The method of claim 16, characterized in that the muscle cell is a cardiomyocyte.

30 18. A muscle cell transduced with a recombinant AAV virion, said virion comprising an AAV vector having a gene encoding acid α -glucosidase operably linked to control elements capable of directing the *in vivo* transcription and translation thereof.

35

19. A method of transducing a mammalian muscle cell, comprising:

5 (a) providing a recombinant AAV virion which comprises an AAV vector having a gene encoding acid α -glucosidase operably linked to control elements capable of directing the *in vivo* transcription and translation thereof; and

10 (b) introducing the recombinant AAV virion into a suitable muscle cell to produce a transduced muscle cell.

20. The method of claim 19, characterized in that the muscle cell is derived from skeletal muscle.

15 21. The method of claim 19, characterized in that the muscle cell is derived from smooth muscle.

20 22. The method of claim 19, characterized in that the muscle cell is derived from cardiac muscle.

25

30

35



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/18, 15/56, 15/86, 5/10, 9/24, C07K 14/505, A61K 31/70, 48/00	A1	(11) International Publication Number: WO 97/26337 (43) International Publication Date: 24 July 1997 (24.07.97)
(21) International Application Number: PCT/US97/00895 (22) International Filing Date: 17 January 1997 (17.01.97) (30) Priority Data: 08/588,355 18 January 1996 (18.01.96) US 08/784,757 16 January 1997 (16.01.97) US (71) Applicants: AVIGEN, INC. [US/US]; Suite 1000, 1201 Harbor Bay Parkway, Alameda, CA 94501 (US). JOHNS HOPKINS UNIVERSITY [US/US]; 720 Rutland Avenue, Baltimore, MD 21205 (US). (72) Inventors: PODSAKOFF, Gregory, M.; 2832 Teal Drive, Fullerton, CA 92635 (US). KESSLER, Paul, D.; 7907 Ellenham Avenue, Baltimore, MD 21204 (US). BYRNE, Barry, J.; 814 Chumleigh Road, Baltimore, MD 21212 (US). KURTZMAN, Gary, J.; 24 Campbell Lane, Menlo Park, CA 94025 (US). (74) Agents: McCracken, Thomas, P. et al.; Robins & Associates, Suite 200, 90 Middlefield Road, Menlo Park, CA 94025 (US).	(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>With amended claims.</i> Date of publication of the amended claims: 2 October 1997 (02.10.97)	
(54) Title: METHODS FOR DELIVERING DNA TO MUSCLE CELLS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VIRIONS		
(57) Abstract <p>The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, <i>in vivo</i> injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the <i>in vitro</i> transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for <i>in vivo</i> secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5 METHODS FOR DELIVERING DNA TO MUSCLE CELLS
 USING RECOMBINANT ADENO-ASSOCIATED VIRUS VIRIONS

Description

10 Technical Field

 The present invention relates generally to DNA delivery methods. More particularly, the invention relates to the use of recombinant adeno-associated virus (AAV) virions for delivery of a
15 selected gene to muscle cells and tissue. The method provides for sustained, high-level expression of the delivered gene.

Background of the Invention

20 Gene delivery is a promising method for the treatment of acquired and inherited diseases. Muscle tissue is an appealing gene delivery target because it is readily accessible, well-differentiated and nondividing. Barr and Leiden (1991) *Science*
25 254:1507-1509. These properties are important in the selection of appropriate delivery strategies to achieve maximal gene transfer.

 Several experimenters have demonstrated the ability to deliver genes to muscle cells with the
30 subsequent systemic circulation of proteins encoded by the delivered genes. See, e.g., Wolff et al. (1990) *Science* 247:1465-1468; Acsadi et al. (1991) *Nature* 352:815-818; Barr and Leiden (1991) *Science* 254:1507-1509; Dhawan et al. (1991) *Science* 254:1509-1512;
35 Wolff et al. (1992) *Human Mol. Genet.* 1:363-369; Eyal et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:4523-4527; Davis et al. (1993) *Hum. Gene Therapy* 4:151-159.

Genes have been delivered to muscle by direct injection of plasmid DNA, such as described by Wolff et al. (1990) *Science* 247:1465-1468; Acsadi et al. (1991) *Nature* 352:815-818; Barr and Leiden (1991) *Science* 254:1507-1509. However, this mode of administration generally results in sustained but low levels of expression. Low but sustained expression levels may be effective in certain situations, such as for providing immunity.

Viral based systems have also been used for gene delivery to muscle. For example, human adenoviruses are double-stranded DNA viruses which enter cells by receptor-mediated endocytosis. These viruses have been considered well suited for gene transfer because they are easy to grow and manipulate and they exhibit a broad host range in vivo and in vitro. Adenoviruses are able to infect quiescent as well as replicating target cells and persist extrachromosomally, rather than integrating into the host genome.

Despite these advantages, adenovirus vectors suffer from several drawbacks which make them ineffective for long term gene therapy. In particular, adenovirus vectors express viral proteins that may elicit an immune response which may decrease the life of the transduced cell. This immune reaction may preclude subsequent treatments because of humoral and/or T cell responses. Furthermore, the adult muscle cell may lack the receptor which recognizes adenovirus vectors, precluding efficient transduction of this cell type using such vectors. Thus, attempts to use adenoviral vectors for the delivery of genes to muscle cells has resulted in poor and/or transitory expression. See, e.g., Quantin et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:2581-2584; Acsadi et al. (1994) *Hum. Mol. Genetics* 3:579-584; Acsadi et al. (1994) *Gene Therapy* 1:338-340; Dai et

al. (1995) *Proc. Natl. Acad. Sci. USA* 92:1401-1405;
Descamps et al. (1995) *Gene Therapy* 2:411-417;
Gilgenkrantz et al. (1995) *Hum. Gene Therapy* 6:1265-
1274.

5 Gene therapy methods based upon surgical
transplantation of myoblasts has also been attempted.
See, e.g., International Publication no. WO 95/13376;
Dhawan et al. (1991) *Science* 254:1509-1512; Wolff et
al. (1992) *Human Mol. Genet.* 1:363-369; Dai et al.
10 (1992) *Proc. Natl. Acad. Sci. USA* 89:10892-10895;
Hamamori et al. (1994) *Hum. Gene Therapy* 5:1349-1356;
Hamamori et al. (1995) *J. Clin. Invest.* 95:1808-1813;
Blau and Springer (1995) *New Eng. J. Med.* 333:1204-
1207; Leiden, J.M. (1995) *New Eng. J. Med.* 333:871-
15 872; Mendell et al. (1995) *New Eng. J. Med.* 333:832-
838; and Blau and Springer (1995) *New Eng. J. Med.*
333:1554-1556. However, such methods require
substantial tissue culture manipulation and surgical
expertise, and, at best, show inconclusive efficacy in
20 clinical trials. Thus, a simple and effective method
of gene delivery to muscle, resulting in long-term
expression of the delivered gene, would be desirable.

Recombinant vectors derived from an adeno-
associated virus (AAV) have been used for gene
25 delivery. AAV is a helper-dependent DNA parvovirus
which belongs to the genus *Dependovirus*. AAV requires
infection with an unrelated helper virus, such as
adenovirus, a herpesvirus or vaccinia, in order for a
productive infection to occur. The helper virus
30 supplies accessory functions that are necessary for
most steps in AAV replication. In the absence of such
infection, AAV establishes a latent state by insertion
of its genome into a host cell chromosome. Subsequent
infection by a helper virus rescues the integrated
35 copy which can then replicate to produce infectious
viral progeny. AAV has a wide host range and is able
to replicate in cells from any species so long as

there is also a successful infection of such cells with a suitable helper virus. Thus, for example, human AAV will replicate in canine cells coinfecting with a canine adenovirus. AAV has not been associated with any human or animal disease and does not appear to alter the biological properties of the host cell upon integration. For a review of AAV, see, e.g., Berns and Bohezky (1987) *Advances in Virus Research* (Academic Press, Inc.) 32:243-307.

The AAV genome is composed of a linear, single-stranded DNA molecule which contains approximately 4681 bases (Berns and Bohezky, *supra*). The genome includes inverted terminal repeats (ITRs) at each end which function in *cis* as origins of DNA replication and as packaging signals for the virus. The internal nonrepeated portion of the genome includes two large open reading frames, known as the AAV *rep* and *cap* regions, respectively. These regions code for the viral proteins involved in replication and packaging of the virion. For a detailed description of the AAV genome, see, e.g., Muzyczka, N. (1992) *Current Topics in Microbiol. and Immunol.* 158:97-129.

The construction of recombinant AAV (rAAV) virions has been described. See, e.g., U.S. Patent Nos. 5,173,414 and 5,139,941; International Publication Numbers WO 92/01070 (published 23 January 1992) and WO 93/03769 (published 4 March 1993); Lebkowski et al. (1988) *Molec. Cell. Biol.* 8:3988-3996; Vincent et al. (1990) *Vaccines 90* (Cold Spring Harbor Laboratory Press); Carter, B.J. (1992) *Current Opinion in Biotechnology* 3:533-539; Muzyczka, N. (1992) *Current Topics in Microbiol. and Immunol.* 158:97-129; and Kotin, R.M. (1994) *Human Gene Therapy* 5:793-801.

Recombinant AAV virion production generally involves cotransfection of a producer cell with an AAV

vector plasmid and a helper construct which provides AAV helper functions to complement functions missing from the AAV vector plasmid. In this manner, the producer cell is capable of expressing the AAV proteins necessary for AAV replication and packaging. The AAV vector plasmid will include the DNA of interest flanked by AAV ITRs which provide for AAV replication and packaging functions. AAV helper functions can be provided via an AAV helper plasmid that includes the AAV *rep* and/or *cap* coding regions but which lacks the AAV ITRs. Accordingly, the helper plasmid can neither replicate nor package itself. The producer cell is then infected with a helper virus to provide accessory functions, or with a vector which includes the necessary accessory functions. The helper virus transactivates the AAV promoters present on the helper plasmid that direct the transcription and translation of AAV *rep* and *cap* regions. Upon subsequent culture of the producer cells, recombinant AAV virions harboring the DNA of interest, are produced.

Recombinant AAV virions have been shown to exhibit tropism for respiratory epithelial cells (Flotte et al. (1992) *Am. J. Respir. Cell Mol. Biol.* 7:349-356; Flotte et al. (1993) *J. Biol. Chem.* 268:3781-3790; Flotte et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:10613-10617) and neurons of the central nervous system (Kaplitt et al. (1994) *Nature Genetics* 8:148-154). These cell types are well-differentiated, slowly-dividing or postmitotic. Flotte et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:10613-10617; Kaplitt et al. (1994) *Nature Genetics* 8:148-154. The ability of AAV vectors to transduce nonproliferating cells (Podsakoff et al. (1994) *J. Virol.* 68:5656-5666; Russell et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:8915-8919; Flotte et al. (1994) *Am. J. Respir. Cell Mol. Biol.* 11:517-521) along with the attributes of

being inherently defective and nonpathogenic, place AAV in a unique position among gene therapy viral vectors.

5 Despite these advantages, the use of recombinant AAV virions to deliver genes to muscle cells *in vivo* has not heretofore been disclosed.

Summary of the Invention

10 Accordingly, the present invention is based on the surprising and unexpected discovery that recombinant AAV (rAAV) virions provide for efficient delivery of genes and sustained production of therapeutic proteins in various muscle cell types. The invention allows for *in vivo* secretion of the
15 therapeutic protein from transduced muscle cells such that systemic delivery of therapeutic levels of the protein is achieved. These results are seen with both *in vivo* and *in vitro* modes of DNA delivery. Hence, rAAV virions allow delivery of DNA directly to muscle
20 tissue. The ability to deliver and express genes in muscle cells, as well as to provide for secretion of the produced protein from transduced cells, allows the use of gene therapy approaches to treat and/or prevent a wide variety of disorders.

25 Furthermore, the ability to deliver DNA to muscle cells by intramuscular administration *in vivo* provides a more efficient and convenient method of gene transfer.

30 Thus, in one embodiment, the invention relates to a method of delivering a selected gene to a muscle cell or tissue. The method comprises:

(a) providing a recombinant AAV virion which comprises an AAV vector, the AAV vector comprising the selected gene operably linked to control elements
35 capable of directing the *in vivo* transcription and translation of the selected gene; and

(b) introducing the recombinant AAV virion into the muscle cell or tissue.

In particularly preferred embodiments, the selected gene encodes a therapeutic protein, such as erythropoietin (EPO), or the lysosomal enzyme, acid α -glucosidase (GAA).

In another embodiment, the invention is directed to a muscle cell or tissue transduced with a recombinant AAV virion which comprises an AAV vector, the AAV vector comprising a selected gene operably linked to control elements capable of directing the *in vivo* transcription and translation of the selected gene.

In still further embodiments, the invention is directed to a method of treating an acquired or inherited disease in a mammalian subject comprising introducing into a muscle cell or tissue of the subject, *in vivo*, a therapeutically effective amount of a pharmaceutical composition which comprises (a) a pharmaceutically acceptable excipient; and (b) recombinant AAV virions. The recombinant AAV virions comprise an AAV vector, the AAV vector comprising a selected gene operably linked to control elements capable of directing the transcription and translation of the selected gene when present in the subject.

In yet another embodiment, the invention is directed to a method of treating an acquired or inherited disease in a mammalian subject comprising:

(a) introducing a recombinant AAV virion into a muscle cell or tissue *in vitro* to produce a transduced muscle cell. The recombinant AAV virion comprises an AAV vector, the AAV vector comprising a selected gene operably linked to control elements capable of directing the transcription and translation of the selected gene when present in the subject; and

(b) administering to the subject a therapeutically effective amount of a composition

comprising a pharmaceutically acceptable excipient and the transduced muscle cells from step (a).

In a further embodiment, the invention relates to a method for delivering a therapeutically effective amount of a protein systemically to a mammalian subject comprising introducing into a muscle cell or tissue of the subject a pharmaceutical composition which comprises (a) a pharmaceutically acceptable excipient; and (b) recombinant AAV virions, wherein the recombinant AAV virions comprise an AAV vector, the AAV vector comprising a selected gene operably linked to control elements capable of directing the transcription and translation of the selected gene when present in the subject, wherein the introducing is done *in vivo*.

In another embodiment, the invention is directed to a method for delivering a therapeutically effective amount of a protein systemically to a mammalian subject comprising:

(a) introducing a recombinant AAV virion into a muscle cell or tissue *in vitro* to produce a transduced muscle cell, wherein the recombinant AAV virion comprises an AAV vector, the AAV vector comprising a selected gene operably linked to control elements capable of directing the transcription and translation of the selected gene when present in the subject; and

(b) administering to the subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable excipient and the transduced muscle cells from step (a).

In other embodiments, the invention is directed to an AAV vector comprising a gene encoding either erythropoietin (EPO), or acid α -glucosidase (GAA), operably linked to control elements capable of directing the *in vivo* transcription and translation of

the gene, as well as a recombinant AAV (rAAV) virion comprising the vector.

These and other embodiments of the subject invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.

Brief Description of the Figures

Figure 1 shows *in situ* histochemical detection of β -galactosidase expression in murine muscle cells following transduction with rAAV-LacZ as described in Example 3, Part A. In the study, the tibialis anterior muscle of adult Balb/c mice was injected with 8×10^9 rAAV-LacZ. Animals were sacrificed (a) 2, (b) 4, (c) 8, (d) 12, (e) 24, of (f) 32 weeks after injection. The tibialis anterior was excised, and 10 mm sections were stained by X-gal for β -galactosidase histochemistry. The stained tissue samples were photographed at 25X.

Figure 2 shows a section of skeletal muscle two months after injection with rAAV-LacZ as described in Example 3, Part A. The tibialis anterior muscle was processed for *in situ* detection of β -galactosidase expression, and photographed with diffraction-interference contrast optics at 400X.

Figure 3 depicts β -galactosidase expression in Balb/c mice tibialis anterior muscle transduced *in vivo* with rAAV-LacZ as described in Example 3, Part B. Adult Balb/c mice were injected intramuscularly (IM) with various doses of rAAV-LacZ. At 2 and 8 weeks post injection, tissue was harvested for analysis of beta-galactosidase (β -gal). β -gal expression was analyzed by measurement of relative light units (RLU) emitted from muscle homogenates, as detected by luminometer.

Figure 4 shows the secretion of human erythropoietin (hEPO) from transduced myotubes and myoblasts, as described in Example 4. Myotubes

(differentiated cells) or myoblasts (actively dividing cells) were transduced with rAAV-hEPO at a ratio of approximately 10^5 per target cell. Levels of secreted hEPO were analyzed in supernatants at various time points. Baseline levels of hEPO prior to transduction were below the level of detection in both cell populations; the values at each time point represent replicate values \pm standard deviation.

Figure 5 shows the secretion of human erythropoietin (hEPO) by C2C12 myotubes transduced with rAAV-hEPO as described in Example 4. Confluent C2C12 myoblasts were differentiated into myotubes and transduced with 3×10^8 (open bar), 3×10^9 (cross-hatched bar), or 3×10^{10} (solid bar) rAAV-hEPO. Secretion of EPO was measured 3, 8, and 14 days after transduction. Control rAAV-LacZ myotubes secreted <2.5 mU/mL EPO. The bar graph depicts mean production of EPO/well/24 hour as determined in triplicate cultures \pm the standard error of mean (SEM).

Figure 6 shows the secretion of human erythropoietin (hEPO) by primary human myotubes transduced with rAAV-hEPO as described in Example 5. Confluent human myoblasts were differentiated into myotubes by culture for 14 days in reduced-serum media, then transduced with 3×10^8 (open bar), 3×10^9 (cross-hatched bar), or 3×10^{10} (solid bar) rAAV-hEPO. Secretion of EPO was measured 3, 8 and 14 days after transduction. Control myotubes transduced with rAAV-LacZ secreted <2.5 mU/mL EPO. The bar graph depicts mean production of EPO/well/24 hour as determined in triplicate cultures \pm SEM.

Figure 7 depicts the time course of EPO secretion in Balb/c mice after IM injection with rAAV-hEPO. Adult Balb/c mice were injected IM with 1×10^{10} (∇), 3×10^{10} (\blacktriangle), 1×10^{11} (\blacksquare), or 3×10^{11} (\bullet) purified rAAV-LacZ at day = 0, and serum EPO levels

measured at various time points after injection.
Reported values represent means (n=4) \pm SEM.

Figure 8 shows high level expression of acid α -glucosidase (GAA) in human skeletal muscle transduced in vitro with rAAV-hGAA as described in Example 8, Part A. In the study, differentiated human myoblasts were exposed to rAAV-hGAA virions at a MOI of 2×10^5 . Cells were collected at the time points indicated, and GAA activity measured by enzymatic assay. Non-transduced control cells (open bar) and cells transduced with rAAV-LacZ (cross-hatched bar) showed no significant expression of GAA, while cells transduced with rAAV-hGAA (solid bar) showed high levels of GAA activity. The bar graph represents mean GAA activity determined in triplicate cultures \pm SEM.

Figure 9 shows expression of acid α -glucosidase in Balb/c mice tibialis anterior muscle cells that were transduced in vivo with rAAV-hGAA, as described in Example 8, Part B. Adult Balb/c mice were injected intramuscularly (IM) with 4×10^{10} rAAV-hGAA (solid bar) or the same dose of rAAV-LacZ (open bar). At various time points after injection, muscle tissue was harvested for analysis of GAA activity by enzymatic assay. The bar graph shows mean GAA activity determined in five animals (weeks 1 and 4), or in four animals (week 10) \pm SEM.

Detailed Description of the Invention

The practice of the present invention will employ, unless otherwise indicated, conventional methods of virology, microbiology, molecular biology and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, et al. *Molecular Cloning: A Laboratory Manual* (Current Edition); *DNA Cloning: A Practical Approach*, vol. I & II (D. Glover, ed.); *Oligonucleotide Synthesis* (N. Gait, ed.,

Current Edition); *Nucleic Acid Hybridization* (B. Hames & S. Higgins, eds., Current Edition); *Transcription and Translation* (B. Hames & S. Higgins, eds., Current Edition); *CRC Handbook of Parvoviruses*, vol. I & II (P. Tijssen, ed.); *Fundamental Virology*, 2nd Edition, vol. I & II (B.N. Fields and D.M. Knipe, eds.)

As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise.

A. Definitions

In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

The phrase "gene delivery" or "gene transfer" refers to methods or systems for reliably inserting foreign DNA into target cells, such as into muscle cells. Such methods can result in transient or long term expression of genes. Gene transfer provides a unique approach for the treatment of acquired and inherited diseases. A number of systems have been developed for gene transfer into mammalian cells. See, e.g., U.S. Patent No. 5,399,346.

The term "therapeutic protein" refers to a protein which is defective or missing from the subject in question, thus resulting in a disease state or disorder in the subject, or to a protein which confers a benefit to the subject in question, such as an antiviral, antibacterial or antitumor function. A therapeutic protein can also be one which modifies any one of a wide variety of biological functions, such as endocrine, immunological and metabolic functions. Representative therapeutic proteins are discussed more fully below.

By "vector" is meant any genetic element, such as a plasmid, phage, transposon, cosmid,

chromosome, virus, virion, etc., which is capable of replication when associated with the proper control elements and which can transfer gene sequences between cells. Thus, the term includes cloning and expression vehicles, as well as viral vectors.

By "AAV vector" is meant a vector derived from an adeno-associated virus serotype, including without limitation, AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAVX7, etc. AAV vectors can have one or more of the AAV wild-type genes deleted in whole or part, preferably the *rep* and/or *cap* genes (described below), but retain functional flanking ITR sequences (also described below). Functional ITR sequences are necessary for the rescue, replication and packaging of the AAV virion. Thus, an AAV vector is defined herein to include at least those sequences required in *cis* for replication and packaging (e.g., functional ITRs) of the virus. The ITRs need not be the wild-type nucleotide sequences, and may be altered, e.g., by the insertion, deletion or substitution of nucleotides, so long as the sequences provide for functional rescue, replication and packaging.

By "recombinant virus" is meant a virus that has been genetically altered, e.g., by the addition or insertion of a heterologous nucleic acid construct into the particle.

By "AAV virion" is meant a wild-type (wt) AAV virus particle (comprising a linear, single-stranded AAV nucleic acid genome associated with an AAV capsid protein coat). In this regard, single-stranded AAV nucleic acid molecules of either complementary sense, e.g., "sense" or "antisense" strands, can be packaged into any one AAV virion and both strands are equally infectious.

A "recombinant AAV virion," or "rAAV virion" is defined herein as an infectious, replication-defective virus composed of an AAV protein shell,

encapsidating a DNA molecule of interest which is flanked on both sides by AAV ITRs. An rAAV virion is produced in a suitable producer cell which has had an AAV vector, AAV helper functions and accessory
5 functions introduced therein. In this manner, the producer cell is rendered capable of encoding AAV polypeptides that are required for packaging the AAV vector (containing a recombinant nucleotide sequence of interest) into recombinant virion particles for
10 subsequent gene delivery.

The term "transfection" is used to refer to the uptake of foreign DNA by a mammalian cell. A cell has been "transfected" when exogenous DNA has been introduced inside the cell membrane. A number of
15 transfection techniques are known in the art. See, e.g., Graham et al. (1973) *Virology*, 52:456, Sambrook et al. (1989) *Molecular Cloning, a laboratory manual*, Cold Spring Harbor Laboratories, New York, Davis et al. (1986) *Basic Methods in Molecular Biology*,
20 Elsevier, and Chu et al. (1981) *Gene* 13:197. Such techniques can be used to introduce one or more exogenous DNA moieties, such as a plasmid vector and other nucleic acid molecules, into suitable cells. The term refers to both stable and transient uptake of
25 the genetic material.

The term "transduction" denotes the delivery of a DNA molecule to a recipient cell either *in vivo* or *in vitro*, via a replication-defective viral vector, such as via a recombinant AAV virion.

30 By "muscle cell" or "tissue" is meant a cell or group of cells derived from muscle, including but not limited to cells and tissue derived from skeletal muscle; smooth muscle, e.g., from the digestive tract, urinary bladder and blood vessels; and cardiac muscle.
35 The term captures muscle cells both *in vitro* and *in vivo*. Thus, for example, an isolated cardiomyocyte would constitute a "muscle cell" for purposes of the

present invention, as would a muscle cell as it exists in muscle tissue present in a subject *in vivo*. The term also encompasses both differentiated and nondifferentiated muscle cells, such as myocytes, myotubes, myoblasts, cardiomyocytes and cardiomyoblasts.

The term "heterologous" as it relates to nucleic acid sequences such as gene sequences and control sequences, denotes sequences that are not normally joined together, and/or are not normally associated with a particular cell. Thus, a "heterologous" region of a nucleic acid construct or a vector is a segment of nucleic acid within or attached to another nucleic acid molecule that is not found in association with the other molecule in nature. For example, a heterologous region of a nucleic acid construct could include a coding sequence flanked by sequences not found in association with the coding sequence in nature. Another example of a heterologous coding sequence is a construct in which the coding sequence itself is not found in nature (e.g., synthetic sequences having codons different from the native gene). Similarly, a cell transformed with a construct which is not normally present in the cell would be considered heterologous for purposes of this invention. Allelic variation or naturally occurring mutational events do not give rise to heterologous DNA, as used herein.

By "DNA" is meant a polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in double-stranded or single-stranded form, either relaxed and supercoiled. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes single- and double-stranded DNA found, *inter alia*, in linear DNA molecules (e.g., restriction fragments), viruses,

plasmids, and chromosomes. In discussing the structure of particular DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having the sequence homologous to the mRNA). The term captures molecules that include the four bases adenine, guanine, thymine, or cytosine, as well as molecules that include base analogues which are known in the art.

A "gene" or "coding sequence" or a sequence which "encodes" a particular protein, is a nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide *in vitro* or *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the gene are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A gene can include, but is not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence will usually be located 3' to the gene sequence.

The term "control elements" refers collectively to promoter regions, polyadenylation signals, transcription termination sequences, upstream regulatory domains, origins of replication, internal ribosome entry sites ("IRES"), enhancers, and the like, which collectively provide for the replication, transcription and translation of a coding sequence in a recipient cell. Not all of these control elements need always be present so long as the selected coding sequence is capable of being replicated, transcribed and translated in an appropriate host cell.

The term "promoter region" is used herein in its ordinary sense to refer to a nucleotide region

comprising a DNA regulatory sequence, wherein the regulatory sequence is derived from a gene which is capable of binding RNA polymerase and initiating transcription of a downstream (3'-direction) coding sequence.

"Operably linked" refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, control elements operably linked to a coding sequence are capable of effecting the expression of the coding sequence. The control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.

For the purpose of describing the relative position of nucleotide sequences in a particular nucleic acid molecule throughout the instant application, such as when a particular nucleotide sequence is described as being situated "upstream," "downstream," "3'," or "5'" relative to another sequence, it is to be understood that it is the position of the sequences in the "sense" or "coding" strand of a DNA molecule that is being referred to as is conventional in the art.

"Homology" refers to the percent of identity between two polynucleotide or two polypeptide moieties. The correspondence between the sequence from one moiety to another can be determined by techniques known in the art. For example, homology can be determined by a direct comparison of the sequence information between two polypeptide molecules by aligning the sequence information and using readily available computer programs. Alternatively, homology

can be determined by hybridization of polynucleotides under conditions which form stable duplexes between homologous regions, followed by digestion with single-stranded-specific nuclease(s), and size determination of the digested fragments. Two DNA, or two polypeptide sequences are "substantially homologous" to each other when at least about 80%, preferably at least about 90%, and most preferably at least about 95% of the nucleotides or amino acids match over a defined length of the molecules, as determined using the methods above.

By "mammalian subject" is meant any member of the class *Mammalia* including, without limitation, humans and nonhuman primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.

B. General Methods

The present invention provides for the successful transfer of a selected gene to a muscle cell using recombinant AAV virions. The method allows for the direct, *in vivo* injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the *in vitro* transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention also provides for secretion of the produced protein *in vivo*, from transduced muscle cells, such that systemic delivery can be achieved.

Muscle provides a desirable target for gene therapy since muscle cells are readily accessible and

nondividing. However, the present invention also finds use with nondifferentiated muscle cells, such as myoblasts, which can be transduced *in vitro*, and subsequently introduced into a subject.

5 Since muscle has ready access to the circulatory system, a protein produced and secreted by muscle cells and tissue *in vivo* will enter the bloodstream for systemic delivery. Furthermore, since sustained, therapeutic levels of protein secretion
10 from muscle is achieved *in vivo* using the present invention, repeated parenteral delivery is avoided or reduced in frequency such that therapy can be accomplished using only one or few injections. Thus, the present invention provides significant advantages
15 over prior gene delivery methods.

 The recombinant AAV virions of the present invention, including the DNA of interest, can be produced using standard methodology, known to those of skill in the art. The methods generally involve the
20 steps of (1) introducing an AAV expression vector into a producer cell; (2) introducing an AAV helper construct into the producer cell, where the helper construct includes AAV coding regions capable of being expressed in the producer cell to complement AAV
25 helper functions missing from the AAV vector; (3) introducing one or more helper viruses and/or accessory function vectors into the producer cell, wherein the helper virus and/or accessory function vectors provide accessory functions capable of
30 supporting efficient recombinant AAV ("rAAV") virion production in the cell; and (4) culturing the producer cell to produce rAAV virions. The AAV expression vector, AAV helper construct and the helper virus or accessory function vector(s) can be introduced into
35 the producer cell, either simultaneously or serially, using standard transfection techniques.

1. AAV Expression Vectors

AAV expression vectors are constructed using known techniques to at least provide as operatively linked components in the direction of transcription, control elements including a transcriptional initiation region, the DNA of interest and a transcriptional termination region. The control elements are selected to be functional in a mammalian muscle cell. The resulting construct which contains the operatively linked components is bounded (5' and 3') with functional AAV ITR sequences.

The nucleotide sequences of AAV ITR regions are known. See, e.g., Kotin, R.M. (1994) *Human Gene Therapy* 5:793-801; Berns, K.I. "Parvoviridae and their Replication" in *Fundamental Virology*, 2nd Edition, (B.N. Fields and D.M. Knipe, eds.) for the AAV-2 sequence. AAV ITRs used in the vectors of the invention need not have a wild-type nucleotide sequence, and may be altered, e.g., by the insertion, deletion or substitution of nucleotides. Additionally, AAV ITRs may be derived from any of several AAV serotypes, including without limitation, AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAVX7, etc. Furthermore, 5' and 3' ITRs which flank a selected nucleotide sequence in an AAV expression vector need not necessarily be identical or derived from the same AAV serotype or isolate, so long as they function as intended, i.e., to allow for packaging of virions.

Suitable DNA molecules for use in AAV vectors will be less than about 5 kilobases (kb) in size and will include, for example, a gene that encodes a protein that is defective or missing from a recipient subject or a gene that encodes a protein having a desired biological or therapeutic effect (e.g., an antibacterial, antiviral or antitumor function).

Suitable DNA molecules include, but are not limited to, those encoding for proteins used for the treatment of endocrine, metabolic, hematologic, cardiovascular, neurologic, musculoskeletal, urologic, pulmonary and immune disorders, including such disorders as inflammatory diseases, autoimmune, chronic and infectious diseases, such as AIDS, cancer, hypercholesterolemia, insulin disorders such as diabetes, growth disorders, various blood disorders including various anemias, thalassemias and hemophilia; genetic defects such as cystic fibrosis, Gaucher's Disease, Hurler's Disease, adenosine deaminase (ADA) deficiency, emphysema, or the like.

To exemplify the invention, the gene encoding erythropoietin (EPO) can be used. EPO is a glycoprotein hormone produced in fetal liver and adult kidney which acts on progenitor cells in the bone marrow and other hematopoietic tissue to stimulate the formation of red blood cells. Genes encoding human and other mammalian EPO have been cloned, sequenced and expressed, and show a high degree of sequence homology in the coding region across species. Wen et al. (1993) *Blood* 82:1507-1516. The sequence of the gene encoding native human EPO, as well as methods of obtaining the same, are described in, e.g., U.S. Patent Nos. 4,954,437 and 4,703,008, as well as in Jacobs et al. (1985) *Nature* 313:806-810; Lin et al. (1985) *Proc. Natl. Acad. Sci. USA* 82:7580; International Publication Number WO 85/02610; and European Patent Publication Number 232,034 B1. In addition, the sequences of the genes encoding native feline, canine and porcine EPO are known and readily available (GenBank Accession Nos.: L10606; L13027; and L10607, respectively), and the sequence of the gene encoding monkey (*Macaca mulatta*) is also known and available (GenBank Accession No.: L10609). The term "EPO" as used herein refers to the native, full-length

secreted form of EPO, as well as to analogs or derivatives thereof comprising single or multiple amino acid substitutions, deletions or additions which retain EPO function or activity. In this regard, a number of small peptides have been identified which bind to and activate the receptor for EPO. Wrighton et al. (1996) *Science* 273:458-463; Livnah et al. (1996) *Science* 273:464-471. The recombinant AAV virions described herein which include a gene encoding EPO, or encoding an analog or derivative thereof having the same function, are particularly useful in the treatment of blood disorders characterized by defective red blood cell formation, such as in the treatment of anemia. Increased red blood cell production due to the production of EPO can be readily determined by an appropriate indicator, such as by comparing hematocrit measurements pre- and post-treatment, measuring increases in red blood cell count, hemoglobin concentration, or in reticulocyte counts. As described above, the EPO gene is flanked by AAV ITRs.

Alternatively, a nucleotide sequence encoding the lysosomal enzyme acid α -glucosidase (GAA) can be used. GAA functions to cleave α -1,4 and α -1,6 linkages of lysosomal glycogen to release monosaccharides. The sequence of the gene encoding human GAA, as well as methods of obtaining the same, have been previously described (GenBank Accession Numbers: M34424 and Y00839; Martiniuk et al. (1990) *DNA Cell Biol.* 9:85-94; Martiniuk et al. (1986) *Proc. Natl. Acad. Sci. USA* 83:9641-9644; Hoefsloot et al. (1988) *Eur. Mol. Biol. Organ.* 7:1697-1704). Thus, the recombinant AAV virions described herein can include a nucleotide sequence encoding GAA, or encoding an analog or derivative thereof having GAA activity.

The selected nucleotide sequence, such as EPO or another gene of interest, is operably linked to

control elements that direct the transcription or expression thereof in the subject *in vivo*. Such control elements can comprise control sequences normally associated with the selected gene.

5 Alternatively, heterologous control sequences can be employed. Useful heterologous control sequences generally include those derived from sequences encoding mammalian or viral genes. Examples include, but are not limited to, the SV40 early promoter; mouse
10 mammary tumor virus LTR promoter; adenovirus major late promoter (Ad MLP); herpes simplex virus (HSV) promoters; a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter region (CMVIE); a rous sarcoma virus (RSV) promoter; synthetic
15 promoters; hybrid promoters; and the like. In addition, sequences derived from nonviral genes, such as the murine metallothionein gene, will also find use herein. Such promoter sequences are commercially available from, e.g., Stratagene (San Diego, CA).

20 For purposes of the present invention, control elements, such as muscle-specific and inducible promoters, enhancers and the like, will be of particular use. Such control elements include, but are not limited to, those derived from the actin and
25 myosin gene families, such as from the myoD gene family (Weintraub et al. (1991) *Science* 251:761-766); the myocyte-specific enhancer binding factor MEF-2 (Cserjesi and Olson (1991) *Mol. Cell Biol.* 11:4854-4862); control elements derived from the human
30 skeletal actin gene (Muscat et al. (1987) *Mol. Cell Biol.* 7:4089-4099) and the cardiac actin gene; muscle creatine kinase sequence elements (Johnson et al. (1989) *Mol. Cell Biol.* 9:3393-3399) and the murine creatine kinase enhancer (mCK) element; control
35 elements derived from the skeletal fast-twitch troponin C gene, the slow-twitch cardiac troponin C gene and the slow-twitch troponin I gene; hypoxia-

inducible nuclear factors (Semenza et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:5680-5684; Semenza et al. *J. Biol. Chem.* 269:23757-23763); steroid-inducible elements and promoters, such as the glucocorticoid response element (GRE) (Mader and White (1993) *Proc. Natl. Acad. Sci. USA* 90:5603-5607); the fusion consensus element for RU486 induction; elements that provide for tetracycline regulated gene expression (Dhawan et al. (1995) *Somat. Cell. Mol. Genet.* 21:233-240; Shockett et al. (1995) *Proc. Natl. Acad. Sci. USA* 92:6522-6526; and inducible, synthetic humanized promoters (Rivera et al. (1996) *Nature Med.* 2:1028-1032).

These and other regulatory elements can be tested for potential *in vivo* efficacy using the *in vitro* myoblast model, which mimics quiescent *in vivo* muscle physiology, described in the examples below.

The AAV expression vector which harbors the DNA molecule of interest bounded by AAV ITRs, can be constructed by directly inserting the selected sequence(s) into an AAV genome which has had the major AAV open reading frames ("ORFs") excised therefrom. Other portions of the AAV genome can also be deleted, so long as a sufficient portion of the ITRs remain to allow for replication and packaging functions. Such constructs can be designed using techniques well known in the art. See, e.g., U.S. Patent Nos. 5,173,414 and 5,139,941; International Publication Nos. WO 92/01070 (published 23 January 1992) and WO 93/03769 (published 4 March 1993); Lebkowski et al. (1988) *Molec. Cell. Biol.* 8:3988-3996; Vincent et al. (1990) *Vaccines* 90 (Cold Spring Harbor Laboratory Press); Carter, B.J. (1992) *Current Opinion in Biotechnology* 3:533-539; Muzyczka, N. (1992) *Current Topics in Microbiol. and Immunol.* 158:97-129; Kotin, R.M. (1994) *Human Gene Therapy* 5:793-801; Shelling and Smith (1994) *Gene*

Therapy 1:165-169; and Zhou et al. (1994) *J. Exp. Med.* 179:1867-1875.

Alternatively, AAV ITRs can be excised from the viral genome or from an AAV vector containing the same and fused 5' and 3' of a selected nucleic acid construct that is present in another vector using standard ligation techniques, such as those described in Sambrook et al., *supra*. For example, ligations can be accomplished in 20 mM Tris-Cl pH 7.5, 10 mM MgCl₂, 10 mM DTT, 33 µg/ml BSA, 10 mM-50 mM NaCl, and either 40 µM ATP, 0.01-0.02 (Weiss) units T4 DNA ligase at 0°C (for "sticky end" ligation) or 1 mM ATP, 0.3-0.6 (Weiss) units T4 DNA ligase at 14°C (for "blunt end" ligation). Intermolecular "sticky end" ligations are usually performed at 30-100 µg/ml total DNA concentrations (5-100 nM total end concentration). AAV vectors which contain ITRs have been described in, e.g., U.S. Patent no. 5,139,941. In particular, several AAV vectors are described therein which are available from the American Type Culture Collection ("ATCC") under Accession Numbers 53222, 53223, 53224, 53225 and 53226.

Additionally, chimeric genes can be produced synthetically to include AAV ITR sequences arranged 5' and 3' of one or more selected nucleic acid sequences. Preferred codons for expression of the chimeric gene sequence in mammalian muscle cells can be used. The complete chimeric sequence is assembled from overlapping oligonucleotides prepared by standard methods. See, e.g., Edge, *Nature* (1981) 292:756; Nambair et al. *Science* (1984) 223:1299; Jay et al. *J. Biol. Chem.* (1984) 259:6311.

In order to produce rAAV virions, an AAV expression vector is introduced into a suitable producer cell using known techniques, such as by transfection. A number of transfection techniques are generally known in the art. See, e.g., Graham et al.

(1973) *Virology*, 52:456, Sambrook et al. (1989) *Molecular Cloning, a laboratory manual*, Cold Spring Harbor Laboratories, New York, Davis et al. (1986) *Basic Methods in Molecular Biology*, Elsevier, and Chu et al. (1981) *Gene* 13:197. Particularly suitable transfection methods include calcium phosphate coprecipitation (Graham et al. (1973) *Virol.* 52:456-467), direct micro-injection into cultured cells (Capecchi, M.R. (1980) *Cell* 22:479-488), electroporation (Shigekawa et al. (1988) *BioTechniques* 6:742-751), liposome mediated gene transfer (Mannino et al. (1988) *BioTechniques* 6:682-690), lipid-mediated transduction (Felgner et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:7413-7417), and nucleic acid delivery using high-velocity microprojectiles (Klein et al. (1987) *Nature* 327:70-73).

For the purposes of the invention, suitable producer cells for producing rAAV virions include microorganisms, yeast cells, insect cells, and mammalian cells, that can be, or have been, used as recipients of a heterologous DNA molecule. The term includes the progeny of the original cell which has been transfected. Thus, a "producer cell" as used herein generally refers to a cell which has been transfected with an exogenous DNA sequence. Cells from the stable human cell line, 293 (readily available through, e.g., the American Type Culture Collection under Accession Number ATCC CRL1573) are preferred in the practice of the present invention. Particularly, the human cell line 293 is a human embryonic kidney cell line that has been transformed with adenovirus type-5 DNA fragments (Graham et al. (1977) *J. Gen. Virol.* 36:59), and expresses the adenoviral E1a and E1b genes (Aiello et al. (1979) *Virology* 94:460). The 293 cell line is readily transfected, and provides a particularly convenient platform in which to produce rAAV virions.

2. AAV Helper Functions

Producer cells containing the above-described AAV expression vectors must be rendered capable of providing AAV helper functions in order to replicate and encapsidate the nucleotide sequences flanked by the AAV ITRs to produce rAAV virions. AAV helper functions are generally AAV-derived coding sequences which can be expressed to provide AAV gene products that, in turn, function in trans for productive AAV replication. AAV helper functions are used herein to complement necessary AAV functions that are missing from the AAV expression vectors. Thus, AAV helper functions include one, or both of the major AAV ORFs, namely the *rep* and *cap* coding regions, or functional homologues thereof.

By "AAV *rep* coding region" is meant the art-recognized region of the AAV genome which encodes the replication proteins Rep 78, Rep 68, Rep 52 and Rep 40. These Rep expression products have been shown to possess many functions, including recognition, binding and nicking of the AAV origin of DNA replication, DNA helicase activity and modulation of transcription from AAV (or other heterologous) promoters. The Rep expression products are collectively required for replicating the AAV genome. For a description of the AAV *rep* coding region, see, e.g., Muzyczka, N. (1992) *Current Topics in Microbiol. and Immunol.* 158:97-129; and Kotin, R.M. (1994) *Human Gene Therapy* 5:793-801. Suitable homologues of the AAV *rep* coding region include the human herpesvirus 6 (HHV-6) *rep* gene which is also known to mediate AAV-2 DNA replication (Thomson et al. (1994) *Virology* 204:304-311).

By "AAV *cap* coding region" is meant the art-recognized region of the AAV genome which encodes the capsid proteins VP1, VP2, and VP3, or functional homologues thereof. These *cap* expression products are the capsid proteins which are collectively required

for packaging the viral genome. For a description of the AAV cap coding region, see, e.g., Muzyczka, N. and Kotin, R.M. (*supra*).

5 AAV helper functions are introduced into the producer cell by transfecting the cell with an AAV helper construct either prior to, or concurrently with, the transfection of the AAV expression vector. AAV helper constructs are thus used to provide at least transient expression of AAV rep and/or cap genes
10 to complement missing AAV functions that are necessary for productive AAV infection. AAV helper constructs lack AAV ITRs and can neither replicate nor package themselves.

These constructs can be in the form of a
15 plasmid, phage, transposon, cosmid, virus, or virion. A number of AAV helper constructs have been described, such as the commonly used plasmids pAAV/Ad and pIM29+45 which encode both Rep and Cap expression products. See, e.g., Samulski et al. (1989) *J. Virol.*
20 63:3822-3828; and McCarty et al. (1991) *J. Virol.* 65:2936-2945. A number of other vectors have been described which encode Rep and/or Cap expression products. See, e.g., U.S. Patent No. 5,139,941.

Both AAV expression vectors and AAV helper
25 constructs can be constructed to contain one or more optional selectable markers. Suitable markers include genes which confer antibiotic resistance or sensitivity to, impart color to, or change the antigenic characteristics of those cells which have
30 been transfected with a nucleic acid construct containing the selectable marker when the cells are grown in an appropriate selective medium. Several selectable marker genes that are useful in the practice of the invention include the hygromycin B
35 resistance gene (encoding Aminoglycoside phosphotransferase (APH)) that allows selection in mammalian cells by conferring resistance to G418

(available from Sigma, St. Louis, Mo.). Other suitable markers are known to those of skill in the art.

5 3. Accessory Functions

 The producer cell must also be rendered capable of providing non AAV derived functions, or "accessory functions," in order to produce rAAV virions. Accessory functions are non AAV derived
10 viral and/or cellular functions upon which AAV is dependent for its replication. Thus, accessory functions include at least those non AAV proteins and RNAs that are required in AAV replication, including those involved in activation of AAV gene
15 transcription, stage specific AAV mRNA splicing, AAV DNA replication, synthesis of Cap expression products and AAV capsid assembly. Viral-based accessory functions can be derived from any of the known helper viruses.

20 Particularly, accessory functions can be introduced into and then expressed in producer cells using methods known to those of skill in the art. Commonly, accessory functions are provided by infection of the producer cells with an unrelated
25 helper virus. A number of suitable helper viruses are known, including adenoviruses; herpesviruses such as herpes simplex virus types 1 and 2; and vaccinia viruses. Nonviral accessory functions will also find use herein, such as those provided by cell
30 synchronization using any of various known agents. See, e.g., Buller et al. (1981) *J. Virol.* 40:241-247; McPherson et al. (1985) *Virology* 147:217-222; Schlehofer et al. (1986) *Virology* 152:110-117.

 Alternatively, accessory functions can be
35 provided using an accessory function vector. Accessory function vectors include nucleotide sequences that provide one or more accessory

functions. An accessory function vector is capable of being introduced into a suitable producer cell in order to support efficient AAV virion production in the cell. Accessory function vectors can be in the form of a plasmid, phage, transposon or cosmid. Accessory vectors can also be in the form of one or more linearized DNA or RNA fragments which, when associated with the appropriate control elements and enzymes, can be transcribed or expressed in a producer cell to provide accessory functions.

Nucleic acid sequences providing the accessory functions can be obtained from natural sources, such as from the genome of an adenovirus particle, or constructed using recombinant or synthetic methods known in the art. In this regard, adenovirus-derived accessory functions have been widely studied, and a number of adenovirus genes involved in accessory functions have been identified and partially characterized. See, e.g., Carter, B.J. (1990) "Adeno-Associated Virus Helper Functions," in *CRC Handbook of Parvoviruses*, vol. I (P. Tijssen, ed.), and Muzyczka, N. (1992) *Curr. Topics. Microbiol. and Immun.* 158:97-129. Specifically, early adenoviral gene regions E1a, E2a, E4, VAI RNA and, possibly, E1b are thought to participate in the accessory process. Janik et al. (1981) *Proc. Natl. Acad. Sci. USA* 78:1925-1929. Herpesvirus-derived accessory functions have been described. See, e.g., Young et al. (1979) *Prog. Med. Virol.* 25:113. Vaccinia virus-derived accessory functions have also been described. See, e.g., Carter, B.J. (1990), *supra.*, Schlehofer et al. (1986) *Virology* 152:110-117.

As a consequence of the infection of the producer cell with a helper virus, or transfection of the producer cell with an accessory function vector, accessory functions are expressed which transactivate the AAV helper construct to produce AAV Rep and/or Cap

proteins. The Rep expression products excise the recombinant DNA (including the DNA of interest) from the AAV expression vector. The Rep proteins also serve to duplicate the AAV genome. The expressed Cap
5 proteins assemble into capsids, and the recombinant AAV genome is packaged into the capsids. Thus, productive AAV replication ensues, and the DNA is packaged into rAAV virions.

Following recombinant AAV replication, rAAV
10 virions can be purified from the producer cell using a variety of conventional purification methods, such as CsCl gradients. Further, if infection is employed to express the accessory functions, residual helper virus can be inactivated, using known methods. For example,
15 adenovirus can be inactivated by heating to temperatures of approximately 60°C for, e.g., 20 minutes or more. This treatment effectively inactivates only the helper virus since AAV is extremely heat stable while the helper adenovirus is
20 heat labile.

The resulting rAAV virions are then ready for use for DNA delivery, such as in gene therapy applications, for the production of transgenic animals, in vaccination, and particularly for the
25 delivery of genes to a variety of muscle cell types.

4. In vitro and In vivo Delivery of rAAV Virions

Generally, rAAV virions are introduced into a muscle cell using either *in vivo* or *in vitro*
30 transduction techniques. If transduced *in vitro*, the desired recipient muscle cell will be removed from the subject, transduced with rAAV virions and reintroduced into the subject. Alternatively, syngeneic or xenogeneic muscle cells can be used where those cells
35 will not generate an inappropriate immune response in the subject.

Suitable methods for the delivery and introduction of transduced cells into a subject have been described. For example, cells can be transduced in vitro by combining recombinant AAV virions with muscle cells e.g., in appropriate media, and screening for those cells harboring the DNA of interest using conventional techniques such as Southern blots and/or PCR, or by using selectable markers. Transduced cells can then be formulated into pharmaceutical compositions, described more fully below, and the composition introduced into the subject by various techniques, such as by intramuscular, intravenous, subcutaneous and intraperitoneal injection, or by injection into smooth and cardiac muscle, using e.g., a catheter.

For in vivo delivery, the rAAV virions will be formulated into pharmaceutical compositions and will generally be administered parenterally, e.g., by intramuscular injection directly into skeletal or cardiac muscle.

Pharmaceutical compositions will comprise sufficient genetic material to produce a therapeutically effective amount of the protein of interest, i.e., an amount sufficient to reduce or ameliorate symptoms of the disease state in question or an amount sufficient to confer the desired benefit. The pharmaceutical compositions will also contain a pharmaceutically acceptable excipient. Such excipients include any pharmaceutical agent that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Pharmaceutically acceptable excipients include, but are not limited to, liquids such as water, saline, glycerol and ethanol. Pharmaceutically acceptable salts can be included therein, for example, mineral acid salts such as hydrochlorides, hydrobromides,

phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. A thorough discussion of pharmaceutically acceptable excipients is available in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J. 1991).

Appropriate doses will depend on the mammal being treated (e.g., human or nonhuman primate or other mammal), age and general condition of the subject to be treated, the severity of the condition being treated, the particular therapeutic protein in question, its mode of administration, among other factors. An appropriate effective amount can be readily determined by one of skill in the art.

Thus, a "therapeutically effective amount" will fall in a relatively broad range that can be determined through clinical trials. For example, for *in vivo* injection, i.e., injection directly to skeletal or cardiac muscle, a therapeutically effective dose will be on the order of from about 10^6 to 10^{15} of the rAAV virions, more preferably 10^8 to 10^{14} rAAV virions. For *in vitro* transduction, an effective amount of rAAV virions to be delivered to muscle cells will be on the order of 10^8 to 10^{13} of the rAAV virions. The amount of transduced cells in the pharmaceutical compositions will be from about 10^4 to 10^{10} muscle cells, more preferably 10^5 to 10^8 muscle cells. When the transduced cells are introduced to vascular smooth muscle, a lower dose may be appropriate. Other effective dosages can be readily established by one of ordinary skill in the art through routine trials establishing dose response curves.

Dosage treatment may be a single dose schedule or a multiple dose schedule. Moreover, the subject may be administered as many doses as appropriate. One of skill in the art can readily
5 determine an appropriate number of doses.

C. Experimental

Below are examples of specific embodiments for carrying out the present invention. The examples
10 are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts,
15 temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

Materials and Methods

20 Vector constructs

A. Construction of p1909adh1acZ.

Plasmid p1909adh1acZ was used as the helper construct in the following examples and was constructed from plasmid pWadh1acZ. Plasmid pWadh1acZ
25 was constructed by partially digesting plasmid pUC119 (GeneBank Reference Name: U07649, GeneBank Accession Number: U07649) with *Afl*III and *Bsp*HI, blunt-end modifying with the klenow enzyme, and then ligating to form a circular 1732 bp plasmid containing the
30 bacterial origin and the *amp* gene only (the polylinker and F1 origin was removed). The blunted and ligated *Afl*III and *Bsp*HI junction forms a unique *Nsp*I site. The 1732 bp plasmid was cut with *Nsp*I, blunt-end modified with T4 polymerase, and a 20 bp
35 *Hin*DIII-*Hin*CII fragment (blunt-end modified with the klenow enzyme) obtained from the pUC119 polylinker was ligated into the blunted *Nsp*I site of the plasmid.

The *Hind*III site from the blunted polylinker was regenerated, and then positioned adjacent to the bacterial origin of replication. The resulting plasmid was then cut at the unique *Pst*I/*Sse*8387I site, and an *Sse*8387I-*Pvu*II-*Sse*8387I oligonucleotide, having the sequence: 5'-GGCAGCTGCCTGCA-3' (SEQ ID NO.:___), was ligated therein. The remaining unique *Bsp*HI site was cut, blunt-end modified with klenow enzyme, and an *Asc*I linker oligonucleotide, having the sequence: 5'-GAAGGCGCGCCTTC-3' (SEQ ID NO.:___) was ligated therein, eliminating the *Bsp*HI site. The resulting plasmid was called pWee.

In order to create the pWadh_{lacZ} construct, a CMV_{lacZ} expression cassette (comprising a nucleotide sequence flanked 5' and 3' by AAV ITRs, containing the following elements: a CMV promoter, the hGH 1st intron, an adh_{lacZ} fragment and an SV40 early polyadenylation site) was inserted into the unique *Pvu*II site of pWee using multiple steps such that the CMV promoter was arranged proximal to the bacterial *amp* gene of pWee.

More particularly, a CMV_{lacZ} expression cassette was derived from the plasmid psub201CMV, which was constructed as follows. An oligonucleotide encoding the restriction enzyme sites: *Not*I-*Mlu*I-*Sna*BI-*Age*I-*Bst*BI-*Bss*HII-*Nco*I-*Hpa*I-*Bsp*EI-*Pml*I-*Rsr*II-*Not*I and having the following nucleotide sequence: 5'-GCGGCCGCACGCGTACGTACCGGTTCTGAAGCGCGCACGGCCGACCATGGTTAACTCCGGACACGTGCGGACCGCGGCCGC-3' (SEQ ID No.:___) was synthesized and cloned into the blunt-end modified *Kas*I-*Ear*I site (partial) of pUC119 to provide a 2757 bp vector fragment. A 653 bp *Spe*I-*Sac*II fragment containing a nucleotide sequence encoding a CMV immediate early promoter was cloned into the *Sna*BI site of the 2757 bp vector fragment. Further, a 269

bp PCR-produced BstBI-BstBI fragment containing a nucleotide sequence encoding the hGH 1st intron which was derived using the following primers:

5'—AAAATTCGAACCTGGGGAGAAACCAGAG—3' (SEQ ID NO.:___)

5 and 3'—aaaattcgaacaggttaagcgcccctTTG—5' (SEQ ID NO.:___), was cloned into the BstBI site of the 2757 bp vector fragment, and a 135 bp HpaI-BamHI (blunt-end modified) fragment containing the SV40 early polyadenylation site from the pCMV- β plasmid (CLONETECH) was cloned into the HpaI site of the subject vector fragment. The resulting construct was then cut with NotI to provide a first CMV expression cassette.

Plasmid pW1909adh_{lacZ} was constructed as follows. A 4723 bp SpeI-EcoRV fragment containing the AAV rep and cap encoding region was obtained from the plasmid pGN1909 (ATCC Accession Number 69871). The pGN1909 plasmid is a high efficiency AAV helper plasmid having AAV rep and cap genes with an AAV p5 promoter region that is arranged in the construct to be downstream from its normal position (in the wild type AAV genome) relative to the rep coding region. The 4723 bp fragment was blunt-end modified, and AscI linkers were ligated to the blunted ends. The resultant fragment was then ligated into the unique AscI site of pWadh_{lacZ} and oriented such that the AAV coding sequences were arranged proximal to the bacterial origin of replication in the construct.

Plasmid pW1909adh_{lacZ} includes the bacterial beta-galactosidase (β -gal) gene under the transcriptional control of the cytomegalovirus immediate early promoter (CMVIE).

B. Construction of pW1909EPO.

Plasmid pW1909adh_{lacZ} was modified to express human erythropoietin (EPO) by replacing the adh_{lacZ} gene with a 718 base pair PpuMI-NcoI fragment

of human EPO cDNA (Wen et al. (1993) *Blood* 5:1507-1516) and by cloning a 2181 bp *Cla*I-*Eco*RI *lac*Z spacer fragment (noncoding) into the *Pml*I site of the vector.

5 C. Construction of pAAV-GAA.

A plasmid containing the human lysosomal enzyme acid α -glucosidase (GAA) coding region was constructed as follows. A 3.2 kB cDNA clone containing the coding sequence for human GAA beginning
10 207 bps downstream from the initiation codon (GenBank Accession Numbers: M34424 and Y00839; Martiniuk et al. (1990) *DNA Cell Biol.* 9:85-94) was cloned into the *Eco*RI site of Bluescript KS (Stratagene). Additional 5' sequence was generated using polymerase chain
15 reaction (PCR) with reverse-transcribed poly-A mRNA (obtained from normal human fibroblasts) as the template. The 5' primer was constructed with a *Kpn*I restriction site and bps -3 to 12 of the published sequence (Martiniuk et al. (1986) *Proc. Natl. Acad. Sci. USA* 83:9641-9644; Hoefsloot et al. (1988) *Eur. Mol. Biol. Organ.* 7:1697-1704). The 3' primer was synthesized from basepairs 1001 to 1018. Using *Kpn*I and the unique internal *Stu*I site at position 776, the PCR product was ligated to the partial cDNA to form
25 the full-length GAA-encoding plasmid. The full length cDNA was truncated at a unique *Sph*I restriction site, and cloned into the expression vector p1.1c to result in the pAAV-GAA construct having the GAA coding region under transcriptional control of the CMV-IE promoter.

30 The p1.1c expression vector was constructed as follows. pUC119 was partially digested with *Kas*I and *Eae*I, and a 2713 bp vector fragment containing the ampicillin resistance gene, the *coli* 1 origin of replication and the M13 origin of replication, was
35 isolated, blunt end modified, and ligated to a synthetic DNA polylinker encoding the restriction enzyme sites *Not*I-*Mlu*I-*Sna*BI-*Age*I-*Sfu*I-*Bss*HII-*Eag*I-

NcoI-*PmeI*-*BspEI*-*PmlI*-*RsrII*-*NotI*, and having the following nucleotide sequence:

5'-GCGGCCGCACGCGTTGTTAACAACCGGTTCTGAAGCGCG
CAGCGGCCGACCATGGGTTTAAACTCCGGACCACGTGCGGACCGAGCGGCCG-

5 3' (SEQ ID NO.: ____). The ligation was conducted such that the *MluI* end of the polylinker was ligated to the *KasI* side of the plasmid. A 653 bp *SpeI*-*SacII* fragment encoding the CMV immediate-early promoter, a 269 bp PCR-produced *SfuI*-*SfuI* produced fragment
10 encoding the hGH 1st intron (derived using the following primers: 5'-AAAATTCGAACAGGTAAGCGCCCCCTTTG-3' (SEQ ID NO.: ____)) and 3'-AAAATTCGAACCTGGGGAGAAACCAGAG-5' (SEQ ID NO.: ____)), a 183 bp *BssHII*-*BssHII* polylinker fragment from
15 pBluescript II SK-, and a 135 bp *HpaI*-*BamHI* (blunted) fragment containing the SV40 early polyadenylation site from pCMV- β (Stratagene), were cloned into the *SnaBI*, *SfuI*, *BssHII*, and *PmeI* sites, respectively, of the aforementioned plasmid. The orientation of the
20 polylinker relative to the intron and polyadenylation site was intron-polylinker (5'*SacI*-3'*KpnI*)-polyadenylation site. The polylinker was further modified by removing the 88 bp *SacI*-*XhoI* polylinker fragment and replacing it with the following synthetic
25 *SacI* to *XhoI* fragment encoding the restriction enzyme sites *SacI*-*ClaI*-*EcoRI*-*SmaI*-*BamHI*-*XbaI*-*Sall*-*PstI*-*BstXI*-*EcoRV*-*BstXI*-olmeganuclease-*HindIII*-*XhoI*, having the following nucleotide sequence:
5'-GAGCTCAATCGATTGAATTCCCCGGGGATCCTCTAGAGTCGACCTGCAGCC
30 ACTGTGTTGGATATCCAACACACTGGTAGGGATAACAGGGTAATCTCGAG-3' (SEQ ID NO.: ____).

Viruses and Cell Lines

35 Adenovirus type 2 (Ad2), available from the American Type Culture Collection, ATCC, Catalogue Number VR846, was used as helper virus to encapsidate vectors.

The human 293 cell line (Graham et al. (1977) *J. Gen. Virol.* 36:59-72, available from the ATCC under Accession no. CRL1573), which has adenovirus Ela and Elb genes stably integrated in its genome, was cultured in complete Dulbecco's modified Eagle's media (DMEM; Bio-Whittaker, Walkersville, MD) containing 4.5 g/L glucose, 10% heat-inactivated fetal bovine serum (FBS; Hyclone, Logan, Utah), 2 mM glutamine, and 50 units/mL penicillin and 50 µg/mL streptomycin.

The C2C12 murine myoblast cell line, available from the ATCC, Catalogue Number CRL1772, was cultured in DMEM with 20% fetal calf serum (FCS), 1% chick embryo extract and 5 µg/mL gentamicin.

Fetal human skeletal myoblasts (Clonetics) were cultured in Hams F-12 human growth medium, containing 20% FCS and 5 µg/mL gentamicin.

The above cell lines were incubated at 37 °C in 5% CO₂, and were routinely tested and found free of mycoplasma contamination.

Production of Recombinant AAV Virions

Recombinant AAV virions were produced in human 293 cells as follows. Subconfluent 293 cells were cotransfected by standard calcium phosphate precipitation (Wigler et al. (1979) *Proc. Natl. Acad. Sci USA* 76:1373-1376) with one of the AAV vector/helper plasmid constructs, pW1909adhLacZ or pW1909EPO; or with pAAV-GAA and the pW1909 helper plasmid. After 6 hours, the transfected cells were infected with Ad2 in fresh medium at a multiplicity of infection (MOI) of 2, and incubated at 37 °C in 5% CO₂ for 70 hours prior to harvest. Pelleted cells were lysed in Tris buffer (10 mM Tris, 150 mM NaCl, pH 8.0) by three cycles of freeze-thaw. The lysate was clarified of cell debris by centrifugation at 12,000 X g, and the crude-cell lysate was layered onto a cesium

chloride cushion for isopyknic gradient centrifugation. Recombinant AAV virions (rAAV-LacZ, rAAV-hEPO, or rAAV-hGAA virions) were extracted from the resulting gradient by isolating the fractions with an average density of approximately 1.38 g/mL, resuspended in Hepes buffered saline (HBS) containing 50 mM Hepes (pH 7.4) and 150 mM NaCl. The preparations were then heated at 56 °C for approximately 1 hour to inactivate Ad2.

10

Assay of rAAV by Dot-blot Hybridization

Recombinant AAV virions were DNase I digested, proteinase K treated, phenol-chloroform extracted, and DNA precipitated with sodium acetate-glycogen (final concentrations = 0.3 M sodium acetate and 160 µg/mL, respectively). DNA samples were denatured (200 µL of 2X alkaline solution (0.8 M NaOH, 20 mM EDTA) added to DNA sample) for 10 minutes, then added to appropriate wells in a dot-blot apparatus, and blotted onto wet Zeta Probe membrane (BioRad), by applying suction until wells were empty. Then, 400 µL of 1X alkaline solution was added; after 5 minutes, wells were emptied by suction. The membrane was rinsed in 2X SSC (Sambrook et al., supra) for 1 min, drained, air dried on filter paper, then baked in vacuum at 80 °C for 30 min. The membrane was then prehybridized for 30 min at 65 °C with 10 mL hybridization buffer (7% SDS, 0.25 M Sodium Phosphate, pH 7.2, 1 mM EDTA). Buffer was replaced with 10 mL fresh solution, freshly boiled probe added, and hybridized overnight at 65 °C. The membrane was washed twice with 25 mL of wash-1 buffer (5% SDS, 40 mM sodium phosphate, pH 7.2, 1 mM EDTA) for 20 min at 65 °C and twice with wash-2 buffer (1% SDS, 40 mM sodium phosphate, pH 7.2, 1 mM EDTA). The membrane was wrapped in plastic film, exposed to radiographic film, and appropriate dots excised from the membrane

to determine radioactivity by scintillation counting, and quantitated by comparison with standards. Titters of rAAV virion were routinely in the range of approximately 10^{13} genomes/mL.

5

Assay for Contaminating Helper Adenovirus

Contaminating infectious adenovirus was assayed as follows. Samples from the purified rAAV virion stocks were added to 50% confluent 293 cells (cultured in 12 well dishes at 1×10^5 cells/well), and the cultures were passaged for 30 days (e.g., the cultures were split 1 to 5, every 3 days) or until the culture exhibited 100% cytopathic effect (CPE) due to adenovirus infection. Cultures were examined daily for CPE, and the day upon which each experimental culture showed 100% CPE was noted. Reference 293 cell cultures infected with a range of known amounts of adenovirus type-2 (from 0 to 1×10^7 plaque forming units (pfu)/culture) were also prepared and treated in the same manner. A standard curve was then prepared from the data obtained from the reference cultures, where the adenovirus pfu number was plotted against the day of 100% CPE. The titer of infectious adenovirus type-2 in each experimental culture was then readily obtained as determined from the standard curve. The limit of detection of the assay was 100 pfu/mL. The presence of wild-type AAV contamination, analyzed by dot-blot hybridization, was approximately 7 logs lower than recombinant virion concentration.

30

Differentiation of Myoblasts

C2C12 myoblasts were transduced either while actively dividing, or as a differentiated cell culture. Differentiation was induced by placing subconfluent myoblasts in murine differentiation medium (DMEM containing 2% horse serum and standard

35

concentrations of glutamine and penicillin-streptomycin) for an interval of four days prior to transduction in order to induce myoblast fusion and formation of differentiated myotubes.

5 Fetal human skeletal myoblasts were differentiated in human differentiation medium (DMEM containing 10% horse serum and 5 μ g/mL gentamicin). Verification of differentiation was performed by microscopic analysis to determine the presence of
10 multinucleated myotubes in culture.

Example 1

Expression of rAAV-LacZ in Terminally Differentiated Adult Rat Cardiomyocytes

15 The ability of recombinant AAV virions to transduce terminally differentiated adult cardiomyocytes was established *in vitro*. Cardiomyocytes were harvested by coronary perfusion with collagenase of adult rat hearts (Fischer 344,
20 Harlan Sprague Dawley, Indianapolis, IN). Cardiomyocytes were grown on laminin-coated glass coverslips and exposed to rAAV-LacZ virions for 4 hours. After 72 hours, the cells were stained for β -galactosidase activity. AAV expression was detected
25 by blue staining of the binucleated cells. These studies demonstrated the ability of rAAV virions to transduce terminally differentiated cells. The transduction efficiency *in vitro* was 30% of adult cells at a multiplicity of infection (MOI) of 10^4
30 genomes per cell.

Example 2

Stability of rAAV-LacZ Expression In Vivo

Adult Fischer rats were used to analyze
35 expression of transgenes *in vivo*. Incremental doses of rAAV-LacZ virions were injected into the left ventricular apex of the heart using either a

subxyphoid or lateral thoracotomy approach. More particularly, experimental animals were anesthetized with Metofane followed by a subxyphoid incision to expose the diaphragmatic surface of the heart. Apical
5 cardiac injections were performed with a glass micropipette. Recombinant virion was diluted in normal saline and injected at a volume of 20-50 μ L.

At varying times post-injection, hearts were harvested and examined for β -galactosidase production
10 and for the presence of infiltrating mononuclear cells. For 5-Bromo-4-chloro-3-indolyl β -D-galactoside histochemical determination, frozen sections (6 μ m) were fixed in 0.5% glutaraldehyde and stained for β -galactosidase activity as described (Sanes et al.
15 (1986) "Use of Recombinant Retrovirus to Study Post-Implantation Cell Lineage in Mouse Embryos," *EMBO J* 5:3133-3142). Paraffin sections (5 μ m) were stained with hematoxylin/eosin. Sections were examined for infiltrating mononuclear cells.

20 The above-described histochemical studies showed greater than 50% transduction of cardiomyocytes in the region of injection at each time point examined. Further, there was no inflammatory cell infiltrate noted during the course of analysis. β -
25 galactosidase staining was observed to persist in cardiac muscle for at least two months following gene transfer.

Example 3

30 In vivo Transduction of Murine Skeletal Muscle using rAAV-LacZ Virions

Recombinant AAV-LacZ virions were injected into muscle tissue of mice, and transduction assessed by β -gal activity. Particularly, *in vivo* transduction
35 was performed by intramuscular (IM) injection of recombinant AAV virions into the skeletal muscle of healthy 6-8 week old Balb/c mice (Jackson

Laboratories, Bar Harbor, ME, Simonsen Laboratories, Gilroy, CA, or Harlan Laboratories) under either Metofane (Pitman-Moore, Mundelein, IL) or ketamine-xylazine anesthesia. The mid-portion of each tibialis anterior muscle was exposed via a 1 cm incision. Injections into the tibialis anterior were carried out using a micro-capillary tube attached to a Hamilton syringe to administer the following formulations at a depth of 2 mm: phosphate-buffered saline (PBS) alone (negative control); or PBS containing either rAAV-LACZ virions or pW1909adh_{lacZ} plasmids.

Tissue samples of tibialis anterior muscle, forelimb muscle, heart, brain and liver were obtained for analysis of β -galactosidase expression. One tibialis anterior muscle from each animal was processed for cross-sectional β -galactosidase analysis, and total β -galactosidase was determined from a crude homogenate of the other muscle using a chemiluminescent assay.

For histochemical detection of β -galactosidase, muscle samples were snap-frozen in dry ice-cooled isopentane, followed by serial transverse sectioning (10 μ m) and processing according to previously described methods (Sanes et al. (1986) *EMBO J* 5:3133-3142). The cross-sectional area of the tibialis anterior expressing β -galactosidase was determined as follows: after counter-staining with nuclear fast red (Vector Labs), the X-gal stained tissue was digitally photographed and the cross-sectional area of stored images was determined using NIH Image software.

The GALACTO-LIGHT™ (Tropix, Bedford, MA) chemiluminescent reporter assay kit was used to detect total β -galactosidase activity in the entire tibialis anterior muscle. Standard curves were prepared from known amounts of purified β -galactosidase (Sigma, St. Louis, MO) resuspended in non-transduced muscle

homogenate. β -galactosidase activity is expressed as either: nanograms of β -galactosidase, normalized for the entire muscle, minus background activity; or in terms of relative light units (RLU) as quantified by luminometer. Forelimb muscle, cardiac muscle, brain tissue and liver samples were assayed in an identical fashion.

10 A. Time course of β -galactosidase expression.

A single intramuscular injection into the left and right tibialis anterior muscles (under direct vision) was used to deliver 8×10^9 rAAV-LacZ in a PBS vehicle. Four animals were injected with PBS alone. 15 Animals were sacrificed at 2, 4, 8, 12, 24 and 32 weeks after injection, and the tibialis anterior muscle was excised and analyzed for the presence of bacterial β -galactosidase (n=5 for each group) as described above.

20 Efficiency of the LacZ gene transfer was assessed by cross-sectional tissue staining and chemiluminescent assay. As can be seen in Figure 1 and in Table I below, gene expression persisted for at least 32 weeks. In addition, two weeks after 25 injection of the recombinant virions, 18% of the muscle cross-sectional area expressed β -galactosidase, while at 32 weeks, 24% of the muscle cross-sectional area expressed β -galactosidase. Negative control tibialis anterior muscle (obtained from the animals 30 injected with PBS alone) showed no background staining. Muscle β -galactosidase activity was also determined in the contralateral injected muscle. This study also revealed persistent expression for at least 32 weeks, in agreement with the cross-sectional fiber 35 analysis (Table I). Further, the observed β -galactosidase was sustained with minimal inflammatory cell infiltrate. These data demonstrate that rAAV-

LacZ virion administration into muscle results in stable expression of the transgene for at least 8 months.

5 Upon histological examination, positive staining filled the cytoplasm of the transduced myofibers and was observed through large contiguous portions of the muscle. Serial transverse sections revealed that blue staining extended throughout the length of the muscle fiber. Diffraction-interference
10 contrast microscopy revealed a clear delineation between positively and negatively stained myofibers (Figure 2), suggesting that recombinant virion delivery was limited by structural barriers such as epimyseal or perimyseal connective tissue.
15 Homogenates prepared from brain, heart, liver, and forelimb muscle displayed no β -galactosidase activity when compared with the background activity of the negative control animals.

20

25

30

35

Table I
Time Course of β -galactosidase Expression
Following Single Injection with rAAV-LacZ.

Time (weeks)	β -galactosidase expression (ng/muscle)	Percent cross- sectional area expressing β - galactosidase (%)
2	1441 \pm 458	18 \pm 6
4	951 \pm 176	20 \pm 4
8	839 \pm 436	24 \pm 3
12	1878 \pm 521	29 \pm 5
24	2579 \pm 1165	22 \pm 3
32	1242 \pm 484	24 \pm 3

The left and right tibialis anterior muscles were injected with 8×10^9 rAAV-lacZ. One member of the pair of injected muscles was processed for β -galactosidase expression ($n=5 \pm$ SEM). The other muscle was processed for histochemical detection of β -galactosidase and determination of the cross-sectional area of the tibialis anterior expressing β -galactosidase. Mean cross-sectional areas \pm SEM are shown.

B. Dose-response assay.

To determine the effective dose range for rAAV-LacZ *in vivo*, recombinant virions were injected into the tibialis anterior muscle of 6-8 week old Balb/c mice, and transduction assessed by β -galactosidase activity as measured by GLACTO-LIGHT™ relative light units (RLU). As can be seen in Figure 3, at two weeks post-injection, the observed RLU ranged from approximately 0.2×10^7 RLU/muscle (injected with 8×10^8 rAAV-LacZ) to approximately 1.1×10^9 RLU/muscle (injected with 3.6×10^{11} rAAV-LacZ).

The levels of expression of β -galactosidase measured in RLU correspond to the percentage of β -galactosidase-positive muscle fibers on cross-sectional analysis. For example, 0.2×10^7 RLU corresponds to approximately 1% β -galactosidase

positive muscle fibers and 1.1×10^9 RLU corresponds to approximately 60% β -galactosidase positive muscle fibers.

5 C. Comparison of β -galactosidase expression efficiency.

 A comparison of β -galactosidase expression efficiency obtained by in vivo transduction of mice using either rAAV-LacZ virions, or plasmid DNA
10 containing the same LacZ expression cassette (pW1909adhLacZ) was carried out as follows. Either 8×10^9 rAAV-LacZ, or 100 μ g of pW1909adhLacZ, was injected into the tibialis anterior muscle of 6-8 week old Balb/c mice. Two weeks post-injection, β -
15 galactosidase activity was assessed using the GALACTO-LIGHT™ chemiluminescent reporter assay kit, as described above. Administration of the recombinant virions resulted in 1441 ng β -galactosidase/muscle (n=5), while administration of 100 μ g of the plasmid
20 DNA, a typical in vivo plasmid DNA dosage (Whalen et al. (1995) *Hum. Gene Ther.* 4:151-159), resulted in 12 ng β -galactosidase/muscle (n=4). This dosage of pW1909adhLacZ plasmid DNA is equivalent to 2.2×10^{13} single stranded genomes, demonstrating that gene
25 delivery by the recombinant virions was substantially more efficient than delivery of an equal molar quantity of vector DNA.

30

35

Example 4
In vitro Transduction of Murine
Myotubes and Myoblasts

In order to determine if differentiated
5 cultured muscle cells are appropriate targets for
recombinant AAV virion transduction, and to assess the
ability of such cells to express a transduced gene,
the following study was carried out. Murine C2C12
cells were selected since these cells have been
10 extensively studied as a model for mammalian
myogenesis (Blau et al. (1993) *Trends Genet.* 9:269-
274), and can be induced to differentiate by growth in
reduced serum medium.

In the study, C2C12 myoblasts (dividing
15 cells) were seeded in cell culture plates at a density
of 2×10^4 cells/cm², maintained in growth media (GM)
until confluent, split, and then either cultured in GM
or cultured for 5 days in murine DM. Differentiation
was verified by the microscopic presence of
20 multinucleate myotubes, representing fused myoblasts
(differentiated C2C12 cells).

The C2C12 myotubes and myoblasts were
transduced in culture with purified rAAV-hEPO virions
at a MOI of 10^5 in OptiMEM (Gibco BRL). In the
25 myotube cultures, DM was added after virion
adsorption. The culture media of the transduced cells
was changed 24 hours prior to collection of
supernatants at 3, 8 and 14 days following
transduction. Secretion of hEPO was assessed by ELISA
30 using the human erythropoietin Quantikine IVD kit
(available from R and D Systems, Minneapolis, MN)
according to manufacturer's recommendations.

The results of the study show that hEPO is
secreted from both the transduced myotubes and
35 myoblasts. The levels of hEPO secretion increased in
the myotubes over the first seven days post-
transduction (Figure 4). As can be seen by reference

to Figure 5, a dose-dependent increase in the secretion of hEPO was also observed in the transduced C2C12 myotubes. Eight days post-transduction of the myotubes, hEPO levels peaked at >3400 mU/mL. These data demonstrate that transduction with rAAV-hEPO of both myotubes or myoblasts results in hEPO secretion by the transduced cells, and that in short-term myotube cultures, hEPO is synthesized and secreted in a dose-dependent manner.

10

Example 5

In vitro Transduction of Human Myotubes Using rAAV-hEPO Virions

To determine if differentiated primary human muscle cells are able to express hEPO following transduction with rAAV-hEPO, the following study was carried out. Primary fetal human skeletal myoblasts were seeded in cell culture plates at a density of 2×10^4 cells/cm², grown to confluence in appropriate growth media, and then cultured for 14 days in human DM. Differentiation was verified by microscopic examination for multinucleate cells. In vitro transduction was carried out by adding purified rAAV-hEPO virions to the cultured myotubes in OptiMEM medium (Gibco BRL). DM was added to the cultures after virion adsorption. Control cultures were transduced with rAAV-LacZ.

Culture media was changed 24 hours prior to collection of supernatants at day 3, 8 and 14 post transduction. Secreted EPO levels were assayed by ELISA as described above in Example 4.

As can be seen in Figure 6, the transduced human myotubes secreted hEPO into the culture in a dose-dependent manner. No detectable EPO activity was measured in the control cultures. Secretion of EPO increased over the 14-day interval post-transduction. These data demonstrate that primary human myotubes

transduced by recombinant AAV virions are capable of expressing and secreting erythropoietin.

Example 6

5 Systemic Delivery of Human Erythropoietin In vivo
 by Intramuscular Administration of rAAV-hEPO

Recombinant AAV virions encoding hEPO were administered to adult healthy Balb/c mice *in vivo* to determine if a systemic level of hEPO can be produced,
10 and a biological response obtained. At various time points after administration, blood was obtained from the orbital venous plexus under anesthesia. Serum hEPO levels were determined by ELISA as described above. Red cell counts were done by hemocytometer,
15 hematocrit was determined by centrifugation of blood in micro-capillary tubes, and hemoglobin concentration was analyzed by cyanmethemoglobin assay (DMA, Arlington, TX) according to manufacturer's specifications and compared with a standard (Stanbio
20 Laboratory, San Antonio, TX) analyzed at 570 nm on a spectrophotometer. Reticulocytes were analyzed by either new methylene blue stain, or by FACS analysis of thiazole orange stained peripheral blood samples (RETIC-COUNT®, Becton-Dickinson, Mountain View, CA);
25 the results of data obtained by either of these methods were similar.

An initial experiment revealed that high levels of hEPO and elevated hematocrits were maintained for >100 days in mice injected IM with 6.5×10^{11} rAAV-hEPO. Next, adult female Balb/c mice were
30 injected IM in both hind limbs with a single administration of rAAV-hEPO at dosages ranging from 3×10^9 to 3×10^{11} particles. Control animals were injected with rAAV-LacZ. The resulting serum hEPO
35 levels were analyzed and are reported below in Table II. As can be seen, a well-defined dose-response was obtained 20, 41, 62 and 83 days post injection.

The time course of hEPO secretion by animals receiving rAAV-hEPO is depicted in Figure 7. As can be seen, serum levels of hEPO increased with time to plateau at from 6 to 8 weeks after injection.

5 The biological activity of secreted hEPO can be monitored by elevation of hematocrit in the experimental animals. A comparison of circulating hEPO levels versus hematocrit is shown in Table II. The comparison shows that hematocrit increased with
10 time and increasing recombinant virion dose. Further, stable elevation in hematocrit has been observed for up to 40 weeks in a group of experimental animals injected with rAAV-hEPO. Control animals had undetectable levels of hEPO (<2.5 mU/mL, the lower
15 limit of detection for the assay).

These results indicate that persistent and stable high-level secretion of hEPO, with a corresponding elevation in hematocrit, is established following a single IM administration of rAAV-hEPO.

20 In addition, comparison of the expression of hEPO by animals injected IM with rAAV-hEPO (3×10^{11} single-stranded genomes) and animals injected IM with the pW1909EPO plasmid (1.4×10^{13} double-stranded genomes in 100 μ g DNA) shows that the recombinant
25 virions gave rise to significantly greater levels of EPO expression. As reported in Table II, 20 days post-injection, recombinant virion-injected animals had serum levels of 445 ± 98 mU/mL, while the plasmid-injected animals had levels of 8 ± 10 mU/mL. At 41
30 days post-injection, levels in the recombinant virion-treated animals had risen to 725 ± 112 mU/mL, while the levels in the plasmid-treated animals had dropped below the level of detection. The animals receiving rAAV-hEPO exhibited approximately 60-fold more
35 circulating hEPO with 100-fold less input genomes at 20 days post-injection, or approximately 6000-fold greater secretion per genome. At 41 days post-

injection, this difference was even greater, since the plasmid expression was below the level of detection.

5

10

15

20

25

30

35

Table II
EPO Expression and Hematocrit: rAAV-hEPO Dose-Response

Dose	Days after Administration					
	20 days		41 days		62 days	
	EPO	HCT	EPO	HCT	EPO	HCT
3x10 ¹¹	445±98	74.2±1.2	725±112	82.3±1.2	769±61	86.5±1.4
1x10 ¹¹	85±14	72.8±1.5	212±23	79.5±1.7	234±75	83.2±0.2
3x10 ¹⁰	17±5	60.0±3.5	34±17	74.7±3.2	55±28	78.7±2.0
1x10 ¹⁰	3±1	52.9±1.8	11±3	61.5±1.9	12±8	68.4±4.6
3x10 ⁹	<2.5	49.9±1.4	<2.5	53.5±2.5	<2.5	57.0±2.4
i.v.	7±3	54.7±3.2	13±2.0	<64.4±5.3	10.1±0.7	70.8±8
Control	<2.5	48.9±1.0	<2.5	49.1±0.8	<2.5	48.1±0.7
Plasmid	8±10	50±3.0	<2.5	50.2±1.0	<2.5	47.8±0.9
					N.D.	N.D.

Values representing means ± standard deviation (SD). EPO = serum levels of human EPO (mU/mL) in Balb/c mice; HCT = hematocrit (%); N.D. = not done; i.v. = intravenous injection with 3 x 10¹¹ rAAV-hEPO; Plasmid = injection with 100 µg plasmid DNA (1.4 x 10¹³ double-stranded plasmid molecules); Control = injection with 3 x 10¹¹ particles of rAAV-lacZ.

Example 7A Comparison of hEPO Secretion from rAAV-hEPO
Administered by IM or IV Routes

A comparison of the circulating levels of hEPO resulting from IM and IV routes of administration was analyzed to determine which method of gene delivery results in higher levels of systemic hEPO. Balb/c mice were injected with 3×10^{11} rAAV-hEPO using either the IM route as described above, or intravenously (IV) in PBS in a total volume of 50 μ L via the lateral tail vein. Serum hEPO levels were determined by ELISA using the methods described above.

As shown in Table II, hEPO levels resulting from the IV administrations were significantly lower than the group that received the virions by the IM route. In particular, at 20 days post-injection, the IM route resulted in levels of hEPO of 445 ± 98 mU/mL, while the IV route produced 7 ± 3.0 mU/mL. At 41 days post-injection, the EPO level observed with the IM route was 725 ± 112 as compared with 13 ± 2.0 mU/mL by IV, or approximately 60-fold more efficacious. These data demonstrate that the IM route of injection resulted in higher systemic levels of hEPO, and suggest that interstitial delivery in muscle results in improved transduction by the recombinant AAV virions.

Example 8In vitro and In vivo Transduction of
Muscle Cells Using rAAV-GAA Virions

Cardiomyopathy in infancy is frequently due to inherited metabolic disease. One such metabolic disease, glycogen storage disease type II (Pompe's disease) is an inherited cardiomyopathy caused by a deficiency in the lysosomal enzyme, acid α -glucosidase (GAA). GAA functions to cleave α -1,4 and α -1,6 linkages of lysosomal glycogen to release

monosaccharides. Loss of enzyme activity results in accumulation of lysosomal glycogen in striated muscle, and is characterized by lysosomal rupture, contractile apparatus disruption and glycogen infiltration.

5 Currently, no effective treatment is available.

Accordingly, the following studies were carried out to determine whether the recombinant AAV virions of the present invention can be used to obtain long-term expression of GAA in transduced muscle
10 cells.

A. In vitro transduction of human skeletal muscle cells with rAAV-hGAA virions.

Human skeletal myoblasts were seeded in cell
15 culture plates at a density of 2×10^4 cells/cm², grown to confluence in appropriate growth media, and then cultured for 14 days in human DM. Differentiation was verified by microscopic examination for multinucleate cells. In vitro transduction was carried out by
20 adding purified rAAV-hGAA virions at an MOI of 2×10^5 to the cultured myotubes in OptiMEM medium (Gibco BRL). DM was added to the cultures after virion adsorption. Transduced control cultures were established by transducing the myotubes with rAAV-LacZ
25 at the same MOI, and negative controls were established by culturing non-transduced myotubes.

Culture media was changed 24 hours prior to collection of supernatants at day 3, 8 and 14 post transduction. hGAA expression was determined by
30 enzymatic assay. Specifically, cell monolayers were harvested with 0.05% trypsin in Puck's saline A containing 0.02% ethylenediaminetetraacetic acid. After quenching the trypsin with growth media, cells were centrifuged, the cell pellet washed with PBS, and
35 resuspended in distilled water. Following three freeze-thaw cycles, the samples were microfuged at 10,000 x g. Protein in the supernatant was determined

using the Bicinchoninic acid method (Pierce) with bovine serum albumin (BSA) as the standard. GAA activity was measured using cleavage of the glycogen analog 4-methylumbelliferyl- α -D-glucoside, by a
5 modification of a previously described method (Galjaard et al. (1973) *Clin. Chim. Acta.* 49:361-375; Galjaard, H. (1973) *Pediatr. Res.* 7:56). Assays contained 30 μ g protein in 125 μ L water. Two volumes of 200 mM sodium acetate (pH 4.3) and 750 nM 4-
10 methyumbelliferyl- α -D-glucoside (from a stock solution of 200 mM in dimethylsulfoxide) were added and the samples incubated at 37°C for one hour. Reactions were stopped with 625 μ L sodium carbonate (pH 10.7). Once cleaved and alkalinized, the 4-methyumbelliferyl
15 fluoresces. Measurements were made with a fluorescence spectrophotometer with excitation at 365 nm and emission at 448 nm. Assay measurements were compared against 4-methyumbelliferone (Sigma, St. Louis, MO) standards. Zero protein and zero time
20 blanks were used.

The observed GAA activity is reported in Figure 8 which demonstrates that *in vitro* transduction of the human myotubes results in high level GAA expression at day 8 and 14 post transduction.

25

B. *In vivo* transduction of skeletal muscle using rAAV-GAA virions.

Recombinant AAV virions encoding human GAA were administered to adult Balb/c mice *in vivo* to
30 determine if systemic levels of GAA can be produced by the transduced cells. Muscle tissue was isolated at various time points after administration, and processed for GAA activity using an enzymatic assay.

In the study, tibialis anterior muscle in
35 Balb/c mice was surgically exposed, and a single intramuscular injection into the left and right muscles (under direct vision) was used to administer

the following formulations: phosphate-buffered saline (PBS) alone (negative control); or PBS containing either 2×10^{10} rAAV-hGAA or rAAV-LacZ (for a total of 4×10^{10} virions/animal).

5 Tissue samples of tibialis anterior muscle were obtained at 1, 4 and 10 weeks following transduction. The tissue samples were prepared by homogenization in water followed by three freeze-thaw cycles. Freeze-thaw lysates were microcentrifuged,
10 and the resultant supernatant assayed for GAA activity as described above. The results of the study are depicted in Figure 9. As can be seen, stable expression of GAA in the transduced mouse muscle cells was observed for ten weeks, demonstrating that the
15 recombinant AAV virions of the present invention are able to establish efficient expression of a functional lysosomal protein in transduced cells, and thus provide a therapeutic approach for the treatment of glycogen storage disease.

20 Accordingly, novel methods for transferring genes to muscle cells have been described. Although preferred embodiments of the subject invention have been described in some detail, it is understood that obvious variations can be made without departing from
25 the spirit and the scope of the invention as defined by the appended claims.

30

35

Deposits of Strains Useful in Practicing the Invention

A deposit of biologically pure cultures of the following strain was made with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland, under the provisions of the Budapest Treaty. The accession number indicated was assigned after successful viability testing, and the requisite fees were paid. Access to said cultures will be available during pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 CFR 1.14 and 35 USC 122. All restriction on availability of said cultures to the public will be irrevocably removed upon the granting of a patent based upon the application. Moreover, the designated deposits will be maintained for a period of thirty (30) years from the date of deposit, or for five (5) years after the last request for the deposit; or for the enforceable life of the U.S. patent, whichever is longer. Should a culture become nonviable or be inadvertently destroyed, or, in the case of plasmid-containing strains, lose its plasmid, it will be replaced with a viable culture(s) of the same taxonomic description.

This deposit is provided merely as a convenience to those of skill in the art, and is not an admission that a deposit is required. A license may be required to make, use, or sell the deposited materials, and no such license is hereby granted.

<u>Strain</u>	<u>Deposit Date</u>	<u>ATCC No.</u>
pGN1909	July 20, 1995	69871

Claims:

1. A method for producing a composition
useful for delivering a selected gene to a muscle cell
5 or tissue, comprising:
 (a) providing a recombinant adeno-
associated virus (AAV) virion which comprises an AAV
vector having said selected gene operably linked to
control elements capable of directing the *in vivo*
10 transcription and translation thereof; and
 (b) combining the recombinant AAV virion
with a pharmaceutically acceptable vehicle.
2. The method of claim 1, characterized in
15 that the composition is useful for delivering a
selected gene to a muscle cell or tissue derived from
skeletal muscle.
3. The method of claim 2, characterized in
20 that the muscle cell is a skeletal myoblast or a
skeletal myocyte.
4. The method of claim 1, characterized in
that the composition is useful for delivering a
25 selected gene to a muscle cell or tissue derived from
smooth muscle.
5. The method of claim 1, characterized in
that the composition is useful for delivering a
30 selected gene to a muscle cell or tissue derived from
cardiac muscle.
6. The method of claim 5, characterized in
that the muscle cell is a cardiomyocyte.
35

7. The method of any one of claims 1-6, characterized in that the selected gene encodes a therapeutic protein.

5 8. The method of claim 7, characterized in that the therapeutic protein is acid α -glucosidase.

9. The method of any one of claims 1-8, characterized in that the control elements comprise a
10 muscle-specific promoter sequence.

10. The method of any one of claims 1-8, characterized in that the control elements comprise an inducible promoter sequence.

15 11. A muscle cell or tissue transduced *in vitro* with a recombinant AAV virion, said virion comprising an AAV vector having a selected gene operably linked to control elements capable of
20 directing the *in vivo* transcription and translation of said selected gene.

12. The transduced muscle cell of claim 11, characterized in that the muscle cell is a skeletal
25 myoblast or a skeletal myocyte.

13. The transduced muscle cell of claim 11, characterized in that the muscle cell is a cardiomyocyte.

30 14. The transduced muscle cell of any one of claims 11-13, characterized in that the selected gene encodes a therapeutic protein.

35 15. The transduced muscle cell of claim 14, characterized in that the therapeutic protein is acid α -glucosidase.

16. The transduced muscle cell of any one of claims 11-15, characterized in that the control elements comprise a muscle-specific promoter sequence.

5 17. The transduced muscle cell of any one of claims 11-15, characterized in that the control elements comprise an inducible promoter sequence.

10 18. A method of transducing a mammalian muscle cell *in vitro*, comprising:

 (a) providing a recombinant AAV virion which comprises an AAV vector having a selected gene operably linked to control elements capable of directing the *in vivo* transcription and translation of
15 said selected gene; and

 (b) introducing the recombinant AAV virion into a suitable muscle cell to produce a transduced muscle cell.

20 19. The method of claim 18, characterized in that the muscle cell is derived from skeletal muscle.

25 20. The method of claim 19, characterized in that the muscle cell is a skeletal myoblast or a skeletal myocyte.

30 21. The method of claim 18, characterized in that the muscle cell is derived from smooth muscle.

 22. The method of claim 18, characterized in that the muscle cell is derived from cardiac muscle.

35 23. The method of claim 22, characterized in that the muscle cell is a cardiomyocyte.

AMENDED CLAIMS

[received by the International Bureau on 10 August 1997 (10.08.97);
original claims 1-23 replaced by new claims 1-22 (4 pages)]

1. A method for producing a composition
useful for delivering a selected gene to a smooth muscle
5 cell or to smooth muscle tissue, said method comprising:
(a) providing a recombinant adeno-associated
virus (AAV) virion which comprises an AAV vector having
the selected gene operably linked to control elements
capable of directing the *in vivo* transcription and
10 translation thereof; and
(b) combining the recombinant AAV virion with
a pharmaceutically acceptable vehicle.
2. The method of claim 1, characterized in
15 that the selected gene encodes a therapeutic protein.
3. The method of claim 1 or 2, characterized
in that the control elements comprise a muscle-specific
promoter sequence.
20
4. The method of claim 1 or 2, characterized
in that the control elements comprise an inducible
promoter sequence.
- 25 5. A smooth muscle cell transduced with a
recombinant AAV virion, said virion comprising an AAV
vector having a selected gene operably linked to control
elements capable of directing the *in vivo* transcription
and translation of said selected gene.
30
6. The transduced muscle cell of claim 5,
characterized in that the selected gene encodes a
therapeutic protein.
- 35

7. The transduced muscle cell of claim 5 or 6, characterized in that the control elements comprise a muscle-specific promoter sequence.

5 8. The transduced muscle cell of claim 5 or 6, characterized in that the control elements comprise an inducible promoter sequence.

9. A method of transducing a mammalian smooth muscle cell, said method comprising:

10 (a) providing a recombinant AAV virion which comprises an AAV vector having a selected gene operably linked to control elements capable of directing the *in vivo* transcription and translation of said selected gene;
15 and

(b) introducing the recombinant AAV virion into a suitable smooth muscle cell to produce a transduced muscle cell.

20 10. A method for producing a composition useful for delivering to a muscle cell or muscle tissue a gene encoding acid α -glucosidase, said method comprising:

(a) providing a recombinant adeno-associated virus (AAV) virion which comprises an AAV vector having
25 said gene operably linked to control elements capable of directing the *in vivo* transcription and translation thereof; and

(b) combining the recombinant AAV virion with a pharmaceutically acceptable vehicle.

30

11. The method of claim 10, characterized in that the control elements comprise a muscle-specific promoter sequence.

35

12. The method of claim 10, characterized in that the control elements comprise an inducible promoter sequence.

5 13. The method of claim 10, characterized in that the composition is useful for delivering a selected gene to a muscle cell or tissue derived from skeletal muscle.

10 14. The method of claim 13, characterized in that the muscle cell is a skeletal myoblast or a skeletal myocyte.

15 15. The method of claim 10, characterized in that the composition is useful for delivering a selected gene to a muscle cell or tissue derived from smooth muscle.

20 16. The method of claim 10, characterized in that the composition is useful for delivering a selected gene to a muscle cell or tissue derived from cardiac muscle.

25 17. The method of claim 16, characterized in that the muscle cell is a cardiomyocyte.

30 18. A muscle cell transduced with a recombinant AAV virion, said virion comprising an AAV vector having a gene encoding acid α -glucosidase operably linked to control elements capable of directing the *in vivo* transcription and translation thereof.

35

19. A method of transducing a mammalian muscle cell, comprising:

(a) providing a recombinant AAV virion which comprises an AAV vector having a gene encoding acid α -glucosidase operably linked to control elements capable of directing the in vivo transcription and translation thereof; and

(b) introducing the recombinant AAV virion into a suitable muscle cell to produce a transduced muscle cell.

20. The method of claim 19, characterized in that the muscle cell is derived from skeletal muscle.

21. The method of claim 19, characterized in that the muscle cell is derived from smooth muscle.

22. The method of claim 19, characterized in that the muscle cell is derived from cardiac muscle.



FIG. 1A



FIG. 1B



FIG. 1C



FIG. 1D



FIG. 1E



FIG. 1F




FIG. 2

3/8




FIG. 3

4/8




FIG. 4

5/8




FIG. 5




FIG. 6

6/8




FIG. 7

7/8




FIG. 8




FIG. 9

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 97/00895

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 6	C12N15/18 C07K14/505	C12N15/56 A61K31/70	C12N15/86 A61K48/00	C12N5/10	C12N9/24
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols)					
IPC 6 C12N A61K					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where appropriate, of the relevant passages				Relevant to claim No.
X	BLOOD, vol. 86, no. 10, SUPPL.1, 15 November 1995, page 4006 XP000673499 PODSAKOFF, G., ET AL. : "LONG-TERM IN VIVO GENE EXPRESSION IN MUSCLE USING AAV VECTORS" see the whole document ---				1-7, 11-14, 18-20, 22,23
X	MODERN PATHOLOGY, vol. 8, no. 1, January 1995, page 178 XP000673501 KOURTIS, A.P., ET AL. : "CARDIAC GENE THERAPY WITH ADENO-ASSOCIATED VIRUS AS A MEANS OF ACHIEVING GRAFT-SPECIFIC IMMUNO-SUPPRESSION" see the whole document ---				11,13, 18,22,23
-/-					
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.					
* Special categories of cited documents :					
* "A" document defining the general state of the art which is not considered to be of particular relevance			* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
* "E" earlier document but published on or after the international filing date			* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone		
* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)			* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.		
* "O" document referring to an oral disclosure, use, exhibition or other means			* "&" document member of the same patent family		
* "P" document published prior to the international filing date but later than the priority date claimed					
Date of the actual completion of the international search			Date of mailing of the international search report		
16 May 1997			1 0. 06. 97		
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016			Authorized officer Holtorf, S		

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/00895

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 34670 A (CHILDRENS HOSPITAL INC) 21 December 1995 see page 9 ---	1,2,7,9
A	HUMAN GENE THERAPY, vol. 6, October 1995, pages 1329-1341, XP000569718 CLARK, K.R., ET AL. : "CELL LINES FOR THE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS" see the whole document ---	1-23
A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 91, November 1994, pages 11557-11561, XP002030822 TRIPATHY, K.S., ET AL. : "STABLE DELIVERY OF PHYSIOLOGIC LEVELS OF RECOMBINANT ERYTHROPOIETIN TO THE SYSTEMIC CIRCULATION BY INTRAMUSCULAR INJECTION OF REPLICATION-DEFECTIVE ADENOVIRUS" see the whole document ---	1-23
A	TRENDS IN GENETICS, vol. 9, no. 8, 1993, pages 269-274, XP002030823 BLAU, H.M., ET AL. : "MYOBLASTS IN PATTERN FORMATION AND GENE THERAPY" see the whole document -----	1-23

Information on patent family members

PCT/US 97/00895

Patent document
cited in search report

Publication
date

Patent family member(s)

Publication
date

WO 9534670 A

21-12-95

AU	3124395	A
CA	2192215	A
EP	0764213	A

05-01-96
21-12-95
26-03-97



1